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SUMMARY  
 
The survival of B-cells is regulated by the two cytokines B-cell activating factor 
(BAFF) and a proliferation-inducing ligand (APRIL), which bind to the receptors 
transmembrane activator and CAML interactor (TACI), B-cell activating factor receptor 
(BAFF-R), and B-cell maturation antigen (BCMA). Due to the importance of B-cell 
regulation for immunopathological diseases, the BAFF/APRIL system is a potent 
therapeutic target. While an antibody to BAFF is approved in systemic lupus 
erythematodes, the soluble receptor TACI-Fc (atacicept) unexpectedly worsened multiple 
sclerosis. Our lab has recently found that the receptor TACI is shed from activated B-cells 
by the protease ADAM10 releasing endogenous soluble TACI (sTACI) that shares 
essential features with the pharmacological atacicept. TACI exists in two isoforms differing 
in the length of their extracellular domain by covering one or two cysteine rich domains 
(CRDs) (TACI-short (CRD2) and TACI-long (CRD1+CRD2)). The aim of this project is to 
elucidate properties of the two TACI isoforms in their soluble and membrane-bound form. 
First, both soluble isoforms of TACI were recombinantly expressed in serum-free 
cultured HEK.EBNA cells as secreted proteins. The purified isoforms were analyzed by 
Coomassie stained SDS-PAGE, Western blot, N-terminal sequencing, and mass-
spectrometry. This showed that sTACI-long and sTACI-short appeared in different N-
terminal variants, largely due to Furin-cleavage. sTACI-short existed additionally in a C-
terminal truncated version (sTACI-short (16-20-W-68-135)). Analysis and separation by 
size exclusion chromatography (SEC) revealed that the two major sTACI-short forms (1-
20-W-68-154 and 16-20-W-68-135) appeared as monomers and to a small extent as 
higher oligomers. Static light scatter coupled to SEC showed that the majority of sTACI-
long formed homodimers and only a minority appeared in the monomeric state. Both 
recombinant isoforms had no N-linked glycosylation, although they contain one predicted 
N-glycosylation site. 
Next, the ability of the sTACI variants to bind to BAFF and APRIL was analyzed in 
a binding ELISA and their decoy function in a NFκB reporter assay. Both isoforms of 
sTACI showed similar affinities for BAFF, while sTACI-long showed a significantly higher 
affinity to APRIL than sTACI-short. Similar results were obtained by the NFκB reporter 
assay. The comparison of three N-terminal variants of sTACI-short, namely sTACI-short 
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(1-20-W-68-154), sTACI-short (16-20-W-68-135), and the recombinantly expressed 
sTACI-short (W-68-154) showed no difference in BAFF binding. In contrast, sTACI-short 
(1-20-W-68-154) bound to APRIL with significantly higher affinity when compared with 
sTACI-short (16-20-W-68-135) and sTACI-short (W-68-154). Thus, the N-terminal part 
outside of the CRD2 seems to contribute to APRIL binding. The dimer of sTACI-long 
bound to BAFF and APRIL significantly better than its monomer as seen by both binding 
ELISA and NFκB reporter assay. Finally, CRD1-Fc, CRD2-Fc, CRD1+CRD2-Fc, and the 
related CRD1+CRD2-Fc-a obtained from Pascal Schneider (University of Lausanne, 
Switzerland) as Fc-fused homodimers were analyzed in comparison. CRD1-Fc showed 
only weak ligand interaction, whereas CRD1+CRD2-Fc, CRD1+CRD2-Fc-a, and CRD2-
Fc bound to BAFF and APRIL in a similar manner. This result confirmed a previous 
publication. 
Beside the soluble sTACI variants, the features of the two membrane-bound TACI 
isoforms (TACI-long and TACI-short) were analyzed. TACI-short was expressed and 
constitutively shed in significantly higher amount from transiently transfected HEK293T 
cells than TACI-long. Both membrane-bound isoforms bound to BAFF and APRIL. TACI-
long and TACI-short interacted homotypically and heterotypically with each other in both 
the soluble and membrane-bound form as shown by Co-Immunoprecipitation. Neither of 
the TACI isoforms interacted in any way with BCMA. 
In conclusion, the observed differences in the binding affinity, decoy function and 
oligomerization between both sTACI isoforms provide deeper insight into the interactions 
of TACI with its ligands BAFF and APRIL. These findings could be relevant for the 
understanding of B-cell biology and for future drugs targeting the BAFF/APRIL system.  
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ZUSAMMENFASSUNG 
 
Die zwei Zytokine BAFF (B-cell activating factor) und APRIL (A proliferation-
inducing ligand) regulieren das Überleben der B-Zellen durch die Bindung an die drei 
Rezeptoren TACI (transmembrane activator and CAML interactor), BAFF-R (B-cell 
activating factor receptor) und BCMA (B-cell maturation antigen). Dieses sogenannte 
BAFF/APRIL-System ist aufgrund seiner großen Bedeutung im Rahmen autoimmuner 
Erkrankungen ein wichtiger Angriffspunkt für Therapien. Im Gegensatz zu einem in 
systemischen Lupus erythematodes zugelassenen Antikörper gegen BAFF, führte der 
lösliche Rezeptor TACI-Fc (Atacicept) unerwartet zu einer Verschlechterung im 
Krankheitsverlauf von Patienten mit Multipler Sklerose. Unser Labor hat vor kurzem 
entdeckt, dass der Rezeptor TACI auf aktivierten B-Zellen von der Protease ADAM10 
geschnitten wird und so auch als endogener löslicher Rezeptor vorkommt. Dieser lösliche 
Rezeptor weist erhebliche Ähnlichkeiten zum pharmazeutisch hergestellten Atacicept auf. 
TACI existiert in zwei verschieden Isoformen, welche sich in der Länge ihrer 
extrazellulären Domäne vor allem durch die Anzahl Cystein-reicher Domänen (CRD) 
unterscheiden (TACI-long (CRD1+CRD2) und TACI-short (CRD2)). Die Zielsetzung 
dieser Arbeit war es, die Eigenschaften beider TACI Isoformen in löslicher und membran-
gebundener Form zu untersuchen und zu vergleichen. 
Zunächst wurden beide löslichen Isoformen rekombinant in HEK.EBNA Zellen 
hergestellt, wobei diese in serum-freies Medium sezerniert wurden. Anschließend wurden 
beide TACI Isoformen durch SDS-PAGE in Verbindung mit Coomassie Färbung, Western 
Blot, N-terminales Sequenzieren sowie Massenspektrometrie analysiert und 
charakterisiert. Hierbei zeigte sich, dass sowohl sTACI-long als auch sTACI-short in 
verschiedenen N-terminalen Varianten vorkamen, die hauptsächlich durch Furin Spaltung 
erklärt werden konnten. In den sTACI-short Präparationen kam zusätzlich eine C-terminal 
verkürzte Variante (sTACI-short (16-20-W-68-135)) vor. Gelfiltration zeigte, dass die 
beiden Hauptvarianten von sTACI-short (1-20-W-68-154 und 16-20-W-68-135) 
überwiegend Monomere darstellten, wobei kleine Mengen höherer Oligomere 
nachgewiesen werden konnten. Die Charakterisierung von sTACI-long über Gelfiltration 
gekoppelt an statische Lichtstreuungsanalyse offenbarte, dass sTACI-long hauptsächlich 
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als Dimer und nur geringfügig als Monomer vorlag. Die unterschiedlichen Fraktionen von 
sTACI-long (Dimer und Monomer) und sTACI-short (1-20-W-68-154 und 16-20-W-68-
135) konnten mittels Gelfiltration voneinander getrennt werden. Beide rekombinant 
hergestellten Isoformen wiesen keine N-verknüpften Glykosylierungen auf, obwohl beide 
eine vorhergesagte Glykosylierungsstelle besitzen. 
In der Folge wurde das BAFF- und APRIL-Bindevermögen der sTACI Varianten 
mit einem Binde-ELISA (enzyme linked immunosorbant assay) und einem NFκB (nuclear 
factor kappa-light-chain-enhancer of activated B-cells) Reporter System untersucht: Im 
Binde-ELISA zeigten beide Isoformen eine ähnliche Affinität für BAFF, wobei sTACI-long 
APRIL signifikant besser band. Diese Ergebnisse wurden mit dem NFκB Reporter System 
bestätigt. Der Vergleich der drei N-terminalen Varianten von sTACI-short (sTACI-short (1-
20-W-68-154), sTACI-short (16-20-W-68-135)) und das rekombinant exprimierte sTACI-
short (W-68-154)) ergab, dass alle drei Varianten keinen Unterschied bezüglich ihrer 
Bindeeigenschaft zu BAFF aufwiesen. sTACI-short (1-20-W-68-154) band jedoch 
signifikant besser an APRIL als die anderen beiden Varianten. Der N-terminale Teil, 
welcher außerhalb der CRD2 gelegen ist, scheint somit Einfluss auf die Bindefähigkeit zu 
APRIL zu haben. Das Dimer von sTACI-long, welches durch Gelfiltration vom Monomer 
getrennt werden konnte, band BAFF und APRIL signifikant besser als das Monomer im 
Binde-ELISA und NFκB Reporter System. Die von Pascal Schneider (Universität von 
Lausanne, Schweiz) zur Verfügung gestellten TACI-Fc-fusions Homodimere CRD1-Fc, 
CRD2-Fc, CRD1+CRD2-Fc und CRD1+CRD2-Fc-a wurden vergleichend untersucht. 
Dabei zeigte CRD1-Fc kaum Interaktionen mit BAFF und APRIL. CRD1+CRD2-Fc, 
CRD2-Fc und CRD1+CRD2-Fc-a
 
wiesen hingegen ähnliche Affinitäten für BAFF und 
APRIL auf. Diese Ergebnisse bestätigten eine frühere Veröffentlichung. 
Abschließend, untersuchten wir beide Isoformen in ihrer Membran-gebundenen 
Form. TACI-short wurde signifikant mehr auf transient transfizierten Hek293T Zellen 
exprimiert und von der Zellmembran geschnitten als TACI-long. Sowohl TACI-long als 
auch TACI-short waren in der Lage BAFF und APRIL zu binden. Beide Isoformen 
interagierten in Membran-gebundener und löslicher Form miteinander auf homo- und 
heterotypische Art, was wir mit unserer Co-Immunopräzipitation Bestimmung nachweisen 
konnten. Keine der beiden Isoformen zeigte eine Interaktion mit BCMA. 
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Zusammenfassend konnten in dieser Arbeit Unterschiede in der Affinität, Decoy-
Rezeptor Funktionalität und Oligomerisierung zwischen den beiden sTACI Isoformen 
aufgezeigt werden, wodurch das Verständnis für die Regulation des BAFF/APRIL-
Systems erweitert wurde. Dies könnte relevant für die Interpretation verschiedener 
Vorgänge in der B-Zell Biologie sein. Des Weiteren könnten die Erkenntnisse dieser 
Studie von Bedeutung für die Entwicklung neuer direkt das BAFF/APRIL-System 
beeinflussender Medikamente sein.  
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1. INTRODUCTION 
1.1. EPIDEMIOLOGY OF MULTIPLE SCLEROSIS 
 
Multiple sclerosis (MS) is a demyelinating and inflammatory disease of the central 
nervous system (CNS). There are estimated to be approximately 2.5 million cases of MS 
worldwide (1). The male:female ratio is approximately 1:2-3 (2). This ratio seems to 
increase over time. In 1955, the ratio was around 1:1.5 and increased to 1:2.3 by 2000 
(3). The general prevalence of MS in Europe is estimated to be 83 cases per 100.000 
persons with an incidence of 4.3 cases per 100.000 persons (4). The disease onset is 
primarily around the ages of 20-40 (2, 5). A Danish study found that MS decreases life 
expectancy approximately 10 years and increases the risk of death roughly threefold in 
comparison to an age-matched control group from the general population (6). 
The diagnosis of MS is based on the McDonald diagnostic criteria (7, 8). The basis 
for this criteria builds the dissemination of lesions in the CNS in time and place (7). Before 
2010 MS could only be diagnosed when manifestations of two clinical symptoms were at 
least 30 days apart and affecting different sites of the CNS. Since 2010 one episode 
together with the proof of earlier events that are in concordance with the dissemination in 
time and place validated through magnetic resonance imaging (MRI) is enough. This is 
an improvement for patients who can now get the therapy they need at an earlier stage of 
disease (8). MS is clinically characterized by four different courses. Primary-progressive 
(PP), relapsing-remitting (RR), secondary-progressive (SP) and progressive-relapsing 
(PR) (9). In 2013 the progressive-relapsing course of disease was revised and it has since 
been considered as a primary-progressive course of disease which is either active or not 
active (10). 85% of patients start with RRMS and develop PPMS within 10 years of 
disease onset. 15% of patients have PPMS from the start (9, 11, 12). 
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1.2. PATHOGENESIS AND IMMUNOPATHOGENESIS OF 
MULTIPLE SCLEROSIS 
 
A combination of genetic susceptibility together with environmental factors that 
promote disease onset seems like the most probable explanation for disease outbreak 
(13-15). Several studies found elevated prevalence of certain MHC (HLA) antigens in MS 
patients (16-18). In addition to these MHC connected variations, several non-MHC risk 
genes have been identified (19). The geographical distribution exhibits clusters of disease 
incidence with higher prevalence in the northern hemisphere and with increasing distance 
to the equator (20). Thus, migration studies give interesting insights. On the one side, 
immigrants who come to their new residency before reaching adulthood exhibit a risk of 
MS onset equivalent to the population of their new location (21). On the other side, 
immigrants older than 15 years maintain the same MS risk of their original area of 
upbringing. Whether this distribution in MS risk is attributed to exposition to infections, 
living conditions, diet or environmental influences remains unknown (22, 23). Additionally, 
Vitamin D exposition is discussed to contribute to the pathogenesis of MS which could 
explain to some extent the findings observed by the geographical distribution (24, 25). 
(26) 
MS is a chronic CNS disease with detectable lesions that show demyelination, 
inflammation, axonal loss and reactive gliosis (27-32). Only a few other diseases like 
neuromyelitis optica (NMO), central pontine myelinolysis (CPM), acute disseminated 
encephalomyelitis (ADEM) or progressive multifocal leukoencephalopathy (PML) show 
demyelination in the CNS. (26) 
The primary causes of this heterogeneity in MS is not known and believed to be 
quite diverse. An immunologic cause of the disease is suspected (33). Nevertheless, other 
theories suggest, that in some (33), or maybe in all cases (34), the disease onset could 
be attributed to a primary degenerative process. Additionally, viral or bacterial infections 
are proposed to be involved in the primary pathogenesis. Until now no case could be 
attributed to a primary infectious cause (35). Intrathecal IgG synthesis against pathogens 
like chlamydia, HHV 6 and EBV are part of the typical polyspecific reaction of the immune 
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system inside the MS CNS (36-39). Also, an implication of EBV has been hypothesized 
(40), however this remains controversial (41-43). (26) 
Nevertheless, the immunological contribution during early and later phases of 
disease is indisputable. Immunologically, MS was previously believed to be a mainly T-
cell driven disease. Autoreactive T-cells get activated in the periphery, for example as a 
consequence of viral infections. These T-cells manage to cross the blood brain barrier into 
the CNS, where they clonally expand. The invasion into the CNS by immunologic cells 
can be visualized and is characterized by vasogenic edemas (44). Local microglia and 
astrocytes present autoantigens to T-cells. T-cells misjudge these autoantigens (45-49), 
like myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), myelin-
associated glycoprotein (MAG) and myelin proteolipid protein (PLP), and become 
stimulated. T-cells then produce pro- inflammatory cytokines like TNF and Interferon 
gamma. This leads to the recruitment of other cellular parts of the immune system like 
macrophages and B-cells. The destruction of the myelin is then caused by a cooperation 
between T- and B-cells through the production of cytokines, inflammatory mediators, 
cytotoxic cells and autoantibodies. This leads to demyelination and axonal loss that can 
be detected by MRI (50). (29) 
 
1.3. B-CELLS IN MULTIPLE SCLEROSIS 
 
The role of B-cells in MS is still not fully understood, however, lately a prominent 
role is suspected. B-cells exert on the one hand pro-inflammatory and on the other hand 
anti-inflammatory effects (Figure 1). On the anti-inflammatory side, B-cells produce anti-
inflammatory cytokines, stimulate the expansion of Treg cells, reduce the differentiation 
of Th1 and Th17 cells, hinder the activity of macrophages and dendritic cells and produce 
regulatory antibodies as well as neurotrophic factors. On the Pro-inflammatory side, B-
cells lead to the generation of pro-inflammatory cytokines, complement activation, 
autoantibody production and antibody dependent cellular cytotoxicity (ADCC). 
Additionally, B-cells take part in antigen-transport and in antigen-presentation. Thus, B-
cells seem to possess regulatory functions within the immune system (11).  
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Figure 1: Regulatory and inflammatory roles of B-cells 
B-cells are regulators of the immune system. On the one hand, B-cells have anti-inflammatory 
effects as indicated in green as well as pro-inflammatory effects as indicated in red. B-cells 
produce anti-inflammatory cytokines such as IL-10, IL-35 or TGF-ß. These cytokines lead to the 
expansion of Treg cells. The differentiation of Th1 and Th17 cells is reduced and the activity of 
macrophages and dendritic cells is hindered. Additionally, B-cells produce regulatory antibodies 
as well as neurotrophic factors. Pro-inflammatory effects include the production of autoantibodies. 
These autoreactive antibodies can lead to complement activation and antibody dependent cellular 
cytotoxicity (ADCC). B-cells are responsible for producing the pro-inflammatory cytokines TNF, 
IL-6 and LT, and take part in antigen-transport and in antigen-presentation. (11) Figure taken from 
(11). 
 
The prominent role of B-cells in MS can be concluded due to several findings (11, 51, 52): 
B-cells are found in lesions, the leptomeningeal space of MS patients, where the 
form follicle-like aggregates (53), and in early MS lesions as part of the inflammatory 
environment (54). These findings have been linked to SPMS (53) and have also been 
shown at early stages of RRMS (55). 
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Oligoclonal bands (OCBs) are part of the diagnostic criteria of MS (8). OCBs are 
immunoglobulins -mostly IgG- that are intrathecally produced and that can be detected in 
the cerebrospinal fluid (CSF) of MS patients (56). The typical pattern of bands is not yet 
attributable to specific autoantigens. Proteomics revealed that OCBs originate from local 
B-cells in the CFS and brain tissue (57). Ubiquitous self-proteins (58) or myelin obtained 
lipid complexes and lipids (58) were suggested as possible autoantigens (59). Although 
the production of autoantibodies in MS has been well delineated at a descriptive level, the 
mechanism underlying the production of MS autoantibodies and the target antigens 
remain widely unknown. More specific than the OCBs for MS is the ‘MRZ reaction’ inside 
the CNS. It is an immune reaction targeted against viral antigens such as measles, rubella 
and varicella zoster virus (MRZ) which can be detected in 80-100% of MS patients (60, 
61).  
The persistence and stability of the OCBs over an extended time in the CNS of MS 
patients (62) despite immunosuppressive therapies (52) suggests B-cell nurturing 
conditions in MS brains. Astrocytes express a B-cell survival factor (BAFF) and thus could 
play a part in the long-term survival and clonally expansion of B-cells in the CNS (63). 
BAFF expression on astrocytes is upregulated during inflammation (63). Additional 
mediators of B-cell survival like CXCL12 and CXCL13 are found on astrocytes and blood 
vessels (CXCL12) or perivascular in CNS parenchyma (CXCL13) (64). B-cells of the CNS 
are not sequestered in the CNS. B-cells are connected to the periphery through cervical 
draining lymph nodes (65). Moreover, B-cells seem to mature in the draining cervical 
lymph nodes before invading the CNS tissue (66). 
Different transgenic mouse models were used to investigate the function of B-cells 
in autoimmune encephalitis (67-69). These animal models facilitate the analysis of the 
contribution of B-cells to autoimmune diseases. These studies found that B-cells 
contribute to pathogenesis by producing autoantibodies (69) and by presenting antigens 
to T-cells (67). 
Different cell surface markers can be detected during B-cell maturation (Figure 2). 
These cell surface markers (Figure 2) are the target of several B-cell directed therapies 
(52).  
 
  
6 
 
 
Figure 2: Cell surface marker expression during B-cell development 
The blue lines indicate cell surface marker expression during different developmental states of B-
cells. These markers can be the target of mAb therapies (written in black letters above blue lines). 
(52) General expression opinion is not uniform as indicated with the fading blue lines. Figure taken 
from (52). 
 
B-cell depleting drugs like rituximab (anti-CD20 mAb), are highly effective in MS 
patients. CD20 is expressed on B-cells at almost every step of B-cell differentiation. Only, 
Pro-B-cells, Pre-B-I and plasma cells do not express CD20 (Figure 2) (52). After one 
application rituximab reduced clinical relapses and MS brain lesions for 48 weeks (70). 
Rituximab is not approved for MS. However, another anti-CD20 mAb (Ocrelizumab) 
showed similar results and is promising for the treatment of MS (71) and is already 
approved for the treatment of MS (72, 73). 
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1.4. THE BAFF/APRIL-SYSTEM 
 
 The survival of B-cells is regulated by the BAFF/APRIL system. The BAFF/APPRIL 
system consists of the two ligands B-cell activating factor (BAFF/BLyS/TALL-1) and a 
proliferation-inducing ligand (APRIL) and the three receptors B-cell activating factor 
receptor (BAFF-R), B-cell maturation Ag (BCMA) and transmembrane activator and 
CAML interactor (TACI) (Figure 3) (74). The ligands and receptors of the BAFF/APRIL 
belong to the tumor necrosis factor (TNF) superfamily system. (75) 
 
Figure 3: The BAFF/APRIL-System 
The BAFF/APRIL-system consists of the two ligands BAFF and APRIL and the receptors BAFF-
R, BCMA and TACI. BAFF can bind to all three receptors, while APRIL can only bind to BCMA 
and TACI. BAFF exists as a soluble form that can build trimers and oligomers. APRIL is processed 
intracellularly and forms trimers that bind to proteoglycans (HSPGs). HSPGs are presumed to 
increase the biological activity of APRIL. In addition, to these homotypic formations both BAFF 
and APRIL form heterotrimers that show similar features. BAFF2APRIL1 is comparable to BAFF, 
while BAFF1APRIL2 is comparable to APRIL. Two of the receptors, namely BCMA and TACI, get 
shed from the cell surface and act as decoy receptors. (74) Figure taken from (74). 
 
BAFF and APRIL assemble as homotrimers (76-78), just like TNF and other TNF 
ligand superfamily members (79). BAFF exists in membrane-bound and soluble form (80, 
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81), while APRIL is cut intracellularly in the Golgi apparatus without any as yet observed 
cell surface expression (82). Both ligands exist in diverse variants. BAFF can form a 
homotrimer and a virus-cluster-like 60mer (83). The function and existence of the 60mer 
is controversial and has not yet been endogenously confirmed in humans. The 60mer 
expression could be a consequence of experimental set ups (pH dependency of the 
construct, recombinant protein production) (84, 85). APRIL exists as a homotrimer that 
can be concentrated through its interactions with proteoglycans on the cell surface of B-
cells (86, 87). Additionally, newly found heterotrimeric hybrid versions of BAFF and APRIL 
have been described that share similar features with BAFF- and APRIL homotrimers. 
BAFF2APRIL1 is comparable to BAFF, while BAFF1APRIL2 is comparable to APRIL (88, 
89). The existence of active soluble heterotrimers has already been proven in patients 
with rheumatoid conditions (90). The complexity within the ligands indicates distinct roles 
and functions of these diverse ligand variations in B-cell biology. The existence and 
functions of all constructs in vivo, however, must be shown and further characterized to 
further understand this system. (75) BAFF and APRIL are different in their functional and 
binding qualities:  
BAFF can bind to all three receptors BAFF-R, TACI and BCMA. All variations of 
BAFF can interact and induce downstream pathways after binding to BAFF-R, while only 
oligomeric forms of BAFF (BAFF-60mer) can induce intracellular pathways in TACI (91, 
92) (Figure 4). APRIL can bind to TACI and BCMA, not to BAFF-R. Several findings 
suggest that APRIL needs to be bound to proteoglycans to exert its biological functions. 
Soluble APRIL alone was shown to interact only weekly with BCMA (91). Similar 
observations had been made for TACI (86, 91). APRIL that was crosslinked by 
proteoglycans, however, was able to activate TACI dependent intracellular pathways in 
contrast to the soluble variant (86, 91) (Figure 4). (75) 
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Figure 4: TACI can only be activated by oligomeric forms of BAFF and APRIL 
Trimers of BAFF and APRIL can bind to TACI assembled as a trimer on the cell surface. For 
intracellular NFκB activation six TACI receptors need to be connected to recruit TRAF2 or TRAF6 
trimers. Only BAFF60mer and HSPG-bound trimers are able to connect TACI receptors and 
activate the classical NFκB pathway through the TRAF trimers. (92) Figure taken from (92). 
 
BCMA and TACI exist as soluble receptors in vivo (91, 93, 94). The protease 
gamma-secretase is responsible for BCMA cleavage (94) and the metalloproteinase 
ADAM10 causes extracellular shedding of TACI followed by intracellular processing of the 
resulting stump by gamma-secretase (93). Soluble BCMA (sBCMA) is able to act as a 
decoy receptor for APRIL (94), while soluble TACI (sTACI) can act as a decoy receptor 
for BAFF and APRIL (93). sBCMA and sTACI could be used as possible biomarkers to 
improve patient care, since both soluble receptors are elevated in B-cell driven 
pathologies (95, 96). 
High levels of BAFF are linked to autoimmunity (97). In concordance with this, a 
BAFF variant that led to BAFF overexpression in a population of Sardinians was 
connected to MS and systemic lupus erythymatodes (SLE) (98). SLE is a generalized 
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autoimmune disease associated with high levels of BAFF (99). An Anti-BAFF mAb 
(belimumab) is beneficial and already approved for the treatment of SLE (100-103).  
Another attempt to target the BAFF/APRIL system was the mAb atacicept (TACI-
Ig). In principle, atacicept was developed as soluble TACI fused to the Fc domain of 
human IgG1 (104, 105) to capture BAFF and APRIL (104). The Fc part of atacicept 
exhibited mutations to inhibit FcyR interaction and complement binding (106-108). 
Atacicept showed positive effects in rheumatoid arthritis (RA) and, in high doses, in SLE 
(109-113). Unfortunately, atacicept worsened MS. The atacicept in multiple sclerosis 
(ATAMS) trial was terminated due to elevated disease activity in treated patients. The 
group treated with atacicept showed an increase in annual relapse rate in comparison to 
a placebo controlled group (significant results for the application of 25 and 150 mg of 
atacicept) (114-116).  
Several reasons could be responsible for the unexpected effect of atacicept on MS, 
while Rituximab was beneficial (11): 
1. Rituximab and atacicept target different subpools of B-cells with atacicept 
affecting Breg cells (regulatory B-cells). 
2. Atacicept treatment leads to an increase of memory B-cells that could enhance 
inflammatory processes.  
3. In EAE atacicept increased the proinflammatory cytokine IL15 that could 
attribute to the inflammatory process during atacicept treatment. 
4. Atacicept leads to a decrease of Fc-receptor blockage due to decreased levels 
of serum Igs. Fc-receptor blockage is beneficial and obligatory for the effect of 
IVIG treatment in MS patients. 
5. Receptors of the BAFF/APRIL system are expressed on neurons and could 
affect neuronal modulation after inflammation like axonal growth. Atacicept 
inhibits this beneficial process by blocking BAFF and APRIL. 
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1.5. THE AMBIVALENT ROLE OF THE RECEPTOR TACI IN 
IMMUNITY 
 
The ambivalent role of the receptor TACI within the immune system could be a 
possible cause for the unexpected failure of atacicept (TACI-Fc/TACI-Ig) in MS (116). 
Earlier studies in TACI (-/-) deficient mice revealed an interesting role of TACI as on the 
one hand a positive and on the other hand a negative regulator of immunity (117-119). 
One study described that mice with TACI deficient B-cells developed splenomegaly, B-
cell aggregates due to increased levels of B-cells and elevated antibody levels (118). 
Another study found that TACI deficient mice had increased levels of autoantibodies, 
developed autoimmune glomerulonephritis and that in vitro inhibition of TACI on B-cells 
decreased B-cell proliferation and a recombinant receptor containing the internal 
sequencing signal of TACI lead to apoptosis of B-cells (117). Another group investigated 
the immune response of TACI deficient mice and showed that these mice were not 
capable to generate a response to specific antigens (T-independent type II antigens) 
(119). In addition, the diseases common variable immunodeficiency (CVID) and IgA 
deficiency are both associated with mutations of TACI (120-123). Some of these patients 
showed signs of lymphoproliferation and autoimmunity together with immunodeficiency 
(122). These findings justify a closer look at the receptor TACI. 
TACI is expressed on memory B-cells, plasmablasts, plasma cells and a 
subpopulation of activated (CD 27-) B-cells (Figure 2) (52, 124). TACI was firstly 
described as interactor with the protein calcium-modulator and cyclophilin ligand (CAML), 
which leads to induction of NF-AT, AP-1 and the classical NFκB pathway (125). TACI was 
found to be important for Ig class switch (126, 127). MyD88 binding to TACI initiates the 
class-switch recombination (92, 128). Additional functions and intracellular pathways have 
been described for TACI (92) (Figure 5). TACI induces plasma cell differentiation and 
decreases B-cell proliferation through mediation of Blimp-1 expression (129). Inhibition of 
the ICOSL receptor through TACI blocks germinal center reactions and B-cell proliferation 
(130). It was found that TACI stops the noncanonical NFκB pathway (NFκB 2) by 
mediating the degradation of NIK through cIAP-1 (131, 132). Moreover, TACI promotes 
together with TLR4 apoptosis in marginal zone B-cells through induction of FasL and Fas 
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(133). In contrast to TACI’s effect on marginal zone B-cells, TACI decreases apoptosis of 
plasma cells by suppression of Bim (130). Concerning the BAFF/APRIL system, TACI 
decreases BAFF concentration and is a direct competitor with BAFF-R for BAFF (91, 92, 
134, 135).  
 
 
Figure 5: Different effects of TACI 
1. TACI mediated Blimp-1 expression leads to plasma cell differentiation and decreased B-cell 
proliferation. 2. TACI hinders germinal center reactions and B-cell proliferation through ICOSL 
receptor inhibition. 3. TACI leads to degradation of NIK through cIAP-1 and thus stops the 
noncanonical NFκB pathway (NFκB 2). 4. Together with TLR4 TACI promotes apoptosis through 
induction of FasL and Fas in marginal zone B-cells. 5. TACI decreases BAFF concentration and 
is a direct competitor with BAFF-R for BAFF (and BCMA for APRIL (not shown)). 6. Plasma cell 
apoptosis is decreased by suppression of Bim. 7. MyD88 binding to TACI initiates the class-switch 
recombination. (92) Figure taken from (92). 
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TACI interacts with high affinity with the ligands BAFF and APRIL (136-139). TACI 
expresses two CRDs - CRD1 and CRD2. The CRD2 of TACI is responsible for high affinity 
binding (140). The CRDs of TACI share 50% of their sequence and both exhibit the DXL 
motif ((Phe/Tyr/Trp)-Asp-Xaa-Leu-(Val/Thr)-(Arg/Gly)) (140). The DXL motif is part of the 
binding module of TACI (140). The DXL motif binds directly to BAFF and APRIL (140-
144). The role of the CRD1 is not known yet. It is proposed to be responsible for 
dimerization (145) or to be an evolutionary leftover without any function (140). 
In humans, TACI appears in two isoforms with the shorter isoform being the product 
of alternative splicing (140). The splicing variant results from the loss of exon 2 which 
codes the CRD1 of TACI and its replacement with a tryptophan (W) residue (140, 146). 
This leads to changes on the extracellular domain. TACI-long expresses both CRDs, while 
TACI-short only CRD2 (Figure 6). A study examined both isoforms of TACI as full length 
receptors expressed on the cell surface (146). That study discovered that human B-cells 
express both isoforms with the shorter isoform predominating in CD27+ B-cells, splenic 
marginal zone B-cells and TLR9-activated peripheral B-cells and that the shorter isoform 
seems to be more potent in inducing plasma cell differentiation. (146) Both isoforms of 
TACI were able to bind to BAFF and APRIL in transduced murine B-cells (146). 
 
 
Figure 6: Structure of sTACI isoforms 
Human sTACI long and short differ in the length of their extracellular domain. sTACI long 
expresses both CRD1 and CRD2. Alternative splicing in human TACI results in a short form only 
consisting of the CRD2. Illustration of the structure of both proteins was adapted from (146) 
supplementary material and the reported protein sequence for sTACI (93) and the TACI isoforms 
(140). 
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2. OBJECTIVE AND STRATEGY 
 
The aim of this thesis was to get a deeper insight into details of the BAFF-APRIL 
system that regulates B-cell survival. Specifically, features of both isoforms of human 
soluble TACI were analyzed. 
To this end, we produced the two soluble TACI isoforms recombinantly in HEK.EBNA 
cells. These proteins were analyzed by mass spectrometry and N-terminal sequencing 
and characterized for posttranslational modifications (N-linked glycosylation) with 
PNGase F assay. We determined then the MW with size exclusion chromatography (SEC) 
and static light scatter (SLS) coupled to SEC. We assessed the oligomerization by SEC, 
SLS, Western blot and Coomassie stained SDS-PAGE. Next, we investigated both 
soluble isoforms for their functionality within the BAFF/APRIL system. We tested them for 
their binding affinity for BAFF and APRIL by binding ELISA and their decoy function by 
NFκB assay. CRD1+CRD2-Fc, CRD1-Fc, CRD2-Fc, CRD1+CRD2-Fc-a, sTACI-short 
variants with differences in amino acid sequence N-terminal outside of CRD2, and SEC 
separated sTACI-long dimer and monomer were compared for binding affinity. Finally, we 
expressed both isoforms in their full-length form transiently in HEK293T cells and 
analyzed release of soluble receptors, ligand binding and homo- or heterotypic 
interactions. 
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3. MATERIAL AND METHODS 
3.1. MATERIAL  
3.1.1. GENERAL MATERIAL AND MACHINES 
 
The following Kits were used for cloning, measurement of the concentration of 
proteins and determination of MW: 
Table 1: Kits 
Kit Company 
Human TACI/TNFRSF13B DuoSet ELISA R&D Systems 
PierceTM BCA Protein Assay Kit Thermo scientific 
QIAquickTMGel Extraction Kit Qiagen GmbH 
Hispeed® Plasmid Maxi Kit Qiagen GmbH 
Hispeed® Plasmid Midi Kit Qiagen GmbH 
QIAprep® Spin Miniprep Kit Qiagen GmbH 
MinElute® PCR Purification Kit Qiagen GmbH 
Human BCMA/TNFRSF17 DuoSet ELISA R&D Systems 
Gel Filtration LMW Calibration Kit GE Healthcare Life Sciences 
 
Different cell lines that were used: 
Table 2: Cell lines 
Cell line Medium 
HEK293T DMEM-medium 
HEK293.EBNA FreestyleTM293 + Glutamin medium 
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 Different pipettes (Table 3) and consumables (Table 4) and general machines 
(Table 5) used in this thesis: 
Table 3: Pipettes 
Device Company 
Accu-jet® pro Brand® GmbH & Co. KG 
Eppendorf®Reference 2 Eppendorf AG 
 
Table 4: List of consumables 
Product Company 
pipet tips with/without filter  Kisker Biotech GmbH & Co. KG  
Eppendorf tubes Eppendorf AG 
Serological pipets Corning-Costar Corporation 
Cryotubes Kisker Biotech GmbH & Co. KG  
Cell culture plates Nunc® 
Nunc® 96-Well Polystyrene Conical 
Bottom MicroWellTMPlates 
Thermo scientific 
Costar® Assay plate Corning-Costar Corporation 
Corning® 96 well plates Corning-Costar Corporation 
Gloves B. Braun AG 
Steritop filter Merck Millipore  
 
Table 5: General Machines 
Machine Model Company 
Incubator Galaxy 170 S Eppendorf AG 
Hood B-(MxPro)^2-160 BERNER 
INTERNATIONAL GMBH 
Gel-electrophoreses XCell SureLock 
Mini-Cell 
Thermo scientific 
Centrifuge for small volumes Cetrifuge 5417R Eppendorf AG 
Centrifuge for big volumes and 
flow cytometry 
MULTIFUGE X3R 
centrifuge 
Thermo scientific 
Vortex Vortex-Genie 2 Scientific Industries 
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The ingredients of the Gel Filtration LMW Calibration Kit (Table 1): 
Table 6: Content of Gel Filtration LMW (low molecular weight) Calibration Kit  
Protein  Molecular weight 
(Mr) 
Stoke`s Radius1 
(Å) 
Source 
Aprotinin 6500 NA Bovine lung 
Ribonuclease A 13700 16.4 Bovine pancreas 
Carbonic Anhydrase 29000 NA Bovine 
erythrocytes 
Ovalbumin 44000 30.5 Hen egg 
Conalbumin 75000 NA Chicken egg white 
Blue Dextran 2000 Void volume 
 
Columns that were used for size exclusion chromatography (SEC) and static light 
scatter analysis (SLS): 
Table 7: Columns for size exclusion chromatography  
Column Geometric 
column 
volume 
(VC (ml)) 
Recommended 
sample volume 
(μl) during 
calibration 
Application Company 
HiLoad 16/60 
Superdex 75 pg 
120 500 SEC GE Healthcare 
Life Sciences 
Superdex 200 
Increase 10/300 GL 
24 25–500 SLS GE Healthcare 
Life Sciences 
 
 
3.1.2. CELLCULTURE MEDIA, BUFFER AND SOLUTIONS 
 
All buffers were filtered with 0.22 µm MILLIPORE Stericup® Vacuum filters (Merck 
Millipore) before usage. The buffers for protein production were additionally degassed. 
The pH was adjusted to 7.4 with NaOH and HCl if not stated otherwise. Double deionized 
water (dH2O) was generated with a Milli-Q System (Merck Millipore) and used for all 
buffers.  
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The following buffers and media were used for cell and bacteria culture: 
Table 8: Buffers for cell and bacteria culture 
Reagent Amount/concentration Company 
DMEM-medium   
DMEM 500 ml SIGMA-Aldrich® Co.LLC.  
FCS 10%  
P/S 1% GIBCO®  
RPMI-medium   
RPMI (1640) 500 ml SIGMA-Aldrich® Co.LLC  
FCS 10%  
P/S 1% GIBCO®  
Sodium pyruvate 1% GIBCO®  
L-Glutamine 1% GIBCO®  
Nonessential Amino acids 1% GIBCO®  
FreestyleTM293 + Glutamin medium   
FreestyleTM293+Glutamin 1 l GIBCO®  
G418/Geneticin 500 µl GIBCO®  
10%Pluronic® F-68 1% GIBCO®  
Kryo-medium   
FBS Superior 90% Merck Millipore 
DMSO 10% New England BioLabs, 
Inc. 
LB-Medium (1L) pH 7.5 => autoclaved  
Bacto-tryptone 10 g BD Biosciences 
Yeast extract 5 g BD Biosciences 
NaCl 10 g Merck Millipore  
LB-agar (dissolved in 1L LB-
medium) 
Dried => autoclaved  
Agar 15 g Thermo Scientific 
Ampicillin 100 µg/ml SIGMA-Aldrich® Co.LLC. 
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The following buffers were used for protein expression: 
Table 9: Buffers for protein production 
Reagent Amount/concentration Company 
Elution Buffer 1M 
Imidazol 
  
Imidazol 1 M Merck Millipore  
Nacl 0.5 M SIGMA-Aldrich® Co.LLC. 
Na2HPO4 20 mM Merck Millipore  
Elution Buffer without 
Imidazol 
  
Nacl 0.5 M SIGMA-Aldrich® Co.LLC. 
Na2HPO4 20 mM Merck Millipore  
5x Dialysis Buffer   
Na2HPO4 0.1 M Merck Millipore  
Nacl 2.5 M SIGMA-Aldrich® Co.LLC. 
Imidazol 50 mM Merck Millipore  
Cleaning Buffer   
NaOH 1 or 0.5 M SIGMA-Aldrich® Co.LLC. 
System Storage Buffer 1   
Ethanol 20% SIGMA-Aldrich®Co.LLC.  
System Storage Buffer 2   
 NaN3 0.01%  SIGMA-Aldrich® Co.LLC. 
Storage Buffer   
Na2HPO4 20 mM Merck Millipore  
Nacl 0.3 M SIGMA-Aldrich® Co.LLC.  
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The following buffers were used for Enzyme Linked Immunosorbent Assay 
(ELISA), flow cytometry, and Co-Immunoprecipitation (Co-IP): 
 
Table 10: Buffers for ELISA, flow cytometry and Co-IP 
Reagent Amount/concentration Company 
 ELISA  
Reagent Diluent   
PBS 500 ml GIBCO®  
BSA 1% SIGMA-Aldrich® Co.LLC.  
Stop Solution   
H2SO4 1 M Carl Roth®GMBH + 
CO.KG 
 FLOW CYTOMETRY  
Wash Buffer   
PBS 500 ml GIBCO®  
BSA 1% SIGMA-Aldrich® Co.LLC. 
 CO-IP  
Lysis Buffer   
NP-40 0.5% SIGMA-Aldrich® Co.LLC. 
HEPES Buffer (1M) 50 mM SIGMA-Aldrich® Co.LLC. 
Nacl 250 mM SIGMA-Aldrich® Co.LLC. 
EDTA 5 mM SIGMA-Aldrich® Co.LLC. 
Complete protease 
inhibitor mixture 
1 Tablet for 50 ml SIGMA-Aldrich® Co.LLC. 
TBS Buffer   
Tris Hcl (Trizma) 50 mM SIGMA-Aldrich® Co.LLC. 
Nacl 150 mM SIGMA-Aldrich® Co.LLC. 
Elution Buffer   
Glycine 1 M (pH = 3) SIGMA-Aldrich® Co.LLC. 
Neutralization Buffer   
Trizma base/Hcl 1 M (pH= 9) SIGMA-Aldrich® Co.LLC. 
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3.1.3. PRIMERS, VECTORS AND INSERTS USED FOR CLONING  
 
The following oligonucleotides were synthesized by Metabion (Table 11). The 
vectors used for cloning are shown in Table 12.  
 Table 11: Primers for cloning 
Primer Sequence 5`→3` Application 
TACI Nhe 1 
secretion-tag 
forward 
ATTAGCTAGCATGGAGACCGACACCCTGCT
GCTGTGGGTGCTGCTGCTGTGGGTGCCCG
GCAGCACCGGCGACGCCGCCATGAGTGG
CCTGGGCCGG 
soluble TACI 
isoforms 
TACI Xba 1 
secretion-tag 
forward I 
ATTATCTAGAATGGAGACCGACACCCTGCT
GCTGTGGGTGCTGCTGCTGTGGGTGCCCG
GCAGCACCGGCGACGCCGCCATGAGTGG
CCTGGGCCGG 
soluble TACI 
isoforms 
TACI Not 1 His6-
tag reverse  
ATTAGCGGCCGCTCAGTGGTGGTGGTGGT
GGTGCCCCCCCTTCAGCCCCGGGAGAG 
soluble TACI 
isoforms 
TACI Xba 1 
secretion-tag 
forward II 
ATTATCTAGAATGGAGACCGACACCCTGCT
GCTGTGGGTGCTGCTGCTGTGGGTGCCCG
GCAGCACCGGCGACGCCGCCTCACTCAGC
TGCCGCAAG 
soluble TACI 
isoforms 
TACI Nhe 1 HA- 
tag forward  
ATTAGCTAGCAATGTACCCATACGATGTTC
CAGATTACGCTAGTGGCCTGGGCCGG 
CO-IP 
TACI Nhe 1 
FLAG®- tag 
forward  
ATTAGCTAGCAATGGATTACAAGGATGACG
ATGACAAGAGTGGCCTGGGCCGG 
CO-IP 
TACI Not 1 
reverse  
ATTAGCGGCCGCTTATGCACCTGGGCCCC
C 
CO-IP 
PTT5 forward 
 
GGGGTGAGTACTCCCTCTCAAAAGC Sequencing 
PTT5 reverse 
 
GGGGCAGAGATGTCGTAGTCAGG Sequencing 
CMV forward 
 
CGCAAATGGGCGGTAGGCGTG Sequencing 
TACI forward CAGACAACTCGGGAAGG  Sequencing 
TACI reverse TGGCAGGAGCAGGGATC  Sequencing 
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Table 12: Vectors for cloning 
Vector Resistance Origin 
PTT5 Ampicillin Judy King Man Ng 
pcDNA3.1(+) Ampicillin, Puromycin AG Lichtenthaler 
 
Several tags were added to the constructs during cloning: 
Table 13: tag 
Tag DNA sequence 
His6-tag GGGGGGCACCACCACCACCACCACTGA 
HA-tag TACCCATACGATGTTCCAGATTACGCT 
FLAG®-tag GATTACAAGGATGACGATGACAAG 
secretion-tag ATGGAGACCGACACCCTGCTGCTGTGGGTGCTGCTGCTGT
GGGTGCCCGGCAGCACCGGCGACGCCGCC 
 
These restriction enzymes were used for all cloning processes: 
Table 14: Restriction enzymes 
Name of restriction 
enzyme 
Target sequence 
5` → 3` 
Temperature and 
buffer 
Company 
Nhe 1 HF GCTAGC NE CUT SMART 
BUFFER 37 °C 
New England 
BioLabs, Inc. 
Not 1 HF GCGGCCGC NE CUT SMART 
BUFFER 37 °C 
New England 
BioLabs, Inc. 
Xba 1 TCTAGA NE CUT SMART 
BUFFER 37 °C 
New England 
BioLabs, Inc. 
 
All plasmids that were used for the experiments are summarized in Table 15 for 
TACI plasmids and Table 16 for non-TACI plasmids. 
Table 15: TACI plasmids  
Plasmid Resistance Origin 
TACI-long in pcDNA3.1(+) Ampicillin, Puromycin Franziska S. Thaler 
TACI-short in pcDNA3.1(+) Ampicillin, Puromycin Franziska S. Thaler 
sTACI-long in PTT5 Ampicillin Miriam Fichtner 
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sTACI-short in PTT5 Ampicillin Miriam Fichtner 
sTACI-short (W-68-154) in 
PTT5 
Ampicillin Miriam Fichtner 
TACI-long HA-tag in 
pcDNA3.1(+) 
Ampicillin, Puromycin Franziska S. Thaler 
TACI-long FLAG-tag in 
pcDNA3.1(+) 
Ampicillin, Puromycin Franziska S. Thaler 
TACI-short HA-tag in 
pcDNA3.1(+) 
Ampicillin, Puromycin Miriam Fichtner 
TACI-short FLAG-tag in 
pcDNA3.1(+) 
Ampicillin, Puromycin Miriam Fichtner 
 
Table 16: Non-TACI plasmids  
Plasmid Resistance Origin 
Renilla-Luciferase Ampicillin AG Rothenfusser 
Firefly-Luciferase Ampicillin AG Rothenfusser 
BCMA full length Ampicillin OriGene Technologies, Inc. 
BCMA FLAG®-tag in pCMV Ampicillin Sarah Laurent 
 
3.1.4. GELS, DYES AND BUFFERS FOR SDS-PAGE AND COOMASSIE 
STAINING 
 
The following materials were used for SDS-PAGE applications: 
Table 17: Material for SDS-PAGE 
Gels Company 
Novex® Bis-Tris 6-12 % InvitrogenTM 
Novex® Tricine 10-20 % InvitrogenTM 
LOADING DYES  
NuPAGE® LDS Sample Buffer (4X) InvitrogenTM 
Novex® Tricine SDS Sample Buffer (2X) InvitrogenTM 
RUNNING BUFFERS  
Novex® Tricine SDS Running Buffer (10X) InvitrogenTM 
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Novex® Tricine SDS Running Buffer (10X) InvitrogenTM 
MOPS SDS Running Buffer (20X) InvitrogenTM 
SAMPLE REDUCING AGENT  
NuPAGE® Sample Reducing Agent (10X) InvitrogenTM 
 
The following buffers were used for Coomassie staining: 
Table 18: Buffers for Coomassie staining 
Reagent Concentration Company 
Coomassie blue solution   
(w/v) Coomassie brilliant-
blue R-250  
0.1% SERVA Electrophoresis 
GmbH 
Methanol 40% SIGMA-Aldrich® Co.LLC. 
Acetic acid 10% SIGMA-Aldrich® Co.LLC. 
Destain solution   
Methanol 50% SIGMA-Aldrich® Co.LLC. 
Acetic acid 7% SIGMA-Aldrich® Co.LLC. 
Storage solution   
Acetic acid 10% SIGMA-Aldrich® Co.LLC. 
 
3.1.5. ANTIBODIES AND FLUOROCHROMES  
 
The following antibodies were used for Western blot (Table 19), Co-IP/Binding 
ELISA (Table 20) and flow cytometry (Table 21): 
Table 19: Antibodies for Western Blot 
Antibody Company Application Clone 
Monoclonal 
TACI/TNFRSF13B Anti-
human produced in 
mouse (IgG1)  
R&D Systems primary antibody 165609 
Anti-mouse IgG (H+L) 
HRP conjugated 
produced in goat 
Promega GmbH Western blot, 
secondary antibody 
polyclonal 
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Table 20: Antibodies for Co-IP and Binding ELISA 
Antibody Company Application Clone 
Monoclonal Anti-FLAG® 
M2 – Antibody produced 
in mouse (IgG1) 
SIGMA-Aldrich® 
Co.LLC. 
Co-IP (capture Ab), 
Binding ELISA 
(capture Ab) 
M2, 
monoclonal 
Monoclonal Anti-HA.11 
Epitope Tag produced in 
mouse (IgG1) 
BioLegend Co-IP (capture Ab) HA-7, 
monoclonal 
 
Table 21: Antibodies for flow cytometry 
Antibody Company Application Clone 
Monoclonal Anti-FLAG® 
M2 – Antibody produced 
in mouse (IgG1) 
SIGMA-
Aldrich® 
Co.LLC. 
primary antibody 
for binding studies 
M2, monoclonal 
Monoclonal 
TACI/TNFRSF13B Anti-
human produced in 
mouse (IgG1)  
R&D Systems primary antibody 
for expression 
165609, 
monoclonal 
Polyclonal Anti-mouse 
Immunoglobulins/RPE 
produced in goat 
Dako secondary 
antibody 
polyclonal 
 
The fluorochromes that were used for flow cytometry had the following excitation 
and emission values: 
Table 22: Fluorochromes for flow cytometry 
Fluorochrome Excitation Emission 
Phycoerithrin (PE) 565 nm 575 nm 
TO-PRO®-3 Iodide 
(InvitrogenTM) 
642 nm 661 nm 
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3.2. METHODS 
3.2.1. GENERAL METHODS 
3.2.1.1. AGAROSE GEL ELECTROPHORESIS 
 
Agarose gel electrophoresis was used to determine the size, yield and purity of 
PCR products and to scan for positive clones. DNA has a negative net charge and thus 
can be run in an electrical field. Agarose is used as matrix. 
1% Agarose gels in TAE buffer were cast into a self-assembled mold with a comb 
suitable for the ongoing application. Peqgreen DNA/RNA Dye (PEQLAB Biotechnologie 
GmbH) was added in a ratio of 4-6 µl per 100 ml Agarose to the solved gel at 55 °C before 
decanting it to the mold to make DNA bands visible. 2-Log DNA Ladder (New England 
BioLabs, Inc.) was used as a size standard that spans a range from 0.1-10.0 kb. The 
bands consisting of the expected DNA fragments were cut after electrophoresis during 
UV light exposure (λ = 254-366 nm) in a UV light box and stored at -20 °C or purified 
immediately. 
 
3.2.1.2. SPECTROPHOTOMETER 
 
DNA and protein concentrations were measured with a UV-based spectroscopy 
named Nanodrop (Nanodrop 2000, Thermo scientific). Small volumes of sample (1-2 µl) 
were tested by spectrophotometry. The system measures the absorbance (Equation 1) 
of the sample with the blanking value as basis and uses the Beer-Lambert equation 
(Equation 2) to correlate the absorbance to the concentration: 
 
	 =  − 		  
Equation 1: Absorbance 
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 =   
Equation 2: Beer-Lambert 
 
(A = absorbance (A=absorbance units), Ɛ = extinction coefficient, b = path length (cm), c = concentration 
(M))  
 
The absorbance (optical density (OD)) was measured at 260 nm for DNA 
molecules and 280 nm for proteins.  
 
3.2.1.3. SDS-PAGE AND COOMASSIE BRILLIANT BLUE STAINING 
 
Sodium dodecyl sulfate (SDS)-PAGE gels were used to analyze proteins for their 
size, oligomerization, and purity. SDS, the matrix of the gel, lead in combination with 
sample reducing agent (50 mM DTT) and heat denaturation (95 °C for 5 min) to 
denaturation of proteins. Electrophoresis was performed at 70-100 V. Novex® sharp 
prestained Protein Standard (Thermo scientific) that spans a range of 3.5-260 kDa was 
used as size standard. Bis-Tris gels (6-12%) were used to check for protein fractions after 
affinity purification (Table 17). Tricine gels were used for analytical purposes such as 
Western blot (Table 17). After gel-electrophoresis the gel was incubated for 20-30 min in 
Coomassie blue solution (Table 18). Next, destain solution (Table 18) was applied and 
exchanged several times for at least 1 h. To decrease the amount of background staining 
the gel was then incubated in storage solution Table 18 overnight. Analysis was done by 
Odyssey Fc (LI-COR Biosciences) with 700 nm. All steps were carried out at room 
temperature. 
 
3.2.1.4. WESTERN BLOT 
 
Western blot was used to identify proteins after SDS-PAGE. 300-750 ng of Protein 
were loaded on a Tricine gel and run at 70-100 V. The gel was blotted semi dry 
(Amersham pharmacia biotech EPS 3501 XL; GE Healthcare Life Sciences) on a 
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polyvinylidene difluoride (PVDF) membrane (GE Healthcare Life Sciences) for 1.5 h at 60 
mA to transfer the proteins. PBST (0.05% Tween® 20 (Bio-Rad Laboratories GmbH) in 
PBS, pH 7.2-7.4) with 5% milk powder (blocking solution) was used to block the 
membrane for 1 h at room temperature to prevent unspecific binding of the detection 
antibodies to areas where no proteins were transferred. The primary antibody (Table 19), 
diluted in PBST with 5% BSA Fraction V (SERVA Electrophoresis GmbH) to a 
concentration of 1 µg/ml) was added and the membrane was incubated over night at 4 °C. 
All incubation and washing steps were carried out on a shaker. 12-18 h later the primary 
antibody that was not specifically bound to the proteins on the membrane was removed 
by washing the membrane three times with PBST for 10 min at room temperature. Then, 
the membrane was incubated with the secondary antibody that was conjugated with 
horseradish peroxidase (HRP) (Table 19), diluted in PBST with 5% milk powder to a 
concentration of 0.4 µg/ml for 2 h. After incubation the unspecific bound secondary 
antibody was removed with the same washing steps that were used to remove the primary 
antibody. ECL Western Blotting Substrate (Merck Millipore or Pierce™) was applied and 
the membrane was analyzed by Odyssey Fc (LI-COR Biosciences) with 700 nm for the 
marker and the chemiluminescence channel for the light reaction (400-700 nm).  
 
3.2.1.5. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)  
 
Enzyme-linked immunosorbent assay (ELISA) is a quantitative immunoassay. The 
antigen concentration correlates to the substrate turnover caused by an enzyme (for 
example HRP). A dilution series with known concentrations of the measured antigen is 
used to generate a standard curve. The standard curve can be used to calculate 
concentrations of the applied sample.  
An ELISA starts with coating a plate with a capture antibody (Table 20). After 
blocking the plate the antigen is incubated. A detection antibody is added. Either the 
enzyme for the later color reaction is directly bound to the detection antibody or added in 
an additional step (Figure 7).  
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Figure 7: Principle of ELISA 
After coating a plate with a capture antibody, an antigen is added. The antigen gets detected by a 
detection antibody. A color reaction is used to measure the reaction. Adapted from (93) 
 
sTACI and sBCMA ELISA Kits from Table 1 were used to determine the 
concentration of samples prior to consecutive experiments. In both ELISAs the secondary 
antibody was coupled with biotin. Horseradish peroxidase (HRP) conjugated to 
streptavidin was added in a next incubation step. Streptavidin and biotin are able to form 
a strong bond (147). Substrate solution (Mix A (H2O2) and Mix B (Tetramethylbenzidine) 
in a ratio of 1:1) was added and after 20 min incubation the reaction was stopped by the 
addition of stop solution (1 M H2SO4). The peroxidase reaction with tetramethylbenzidine 
and HRP was detected by photometry. Both ELISAs were read out with Victor2 1420 
Multilabel Counter (Perkin Elmer) with 450 nm for the absorbance and 540 nm for the 
background from the plate.  
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3.2.1.6. BICINCHONINIC ACID (BCA) ASSAY 
 
Bicinchoninic acid assay (BCA) was used to determine protein concentration after 
protein expression. Two chemical reactions comprise the basis for this method. First, the 
peptides of the protein lead to the reduction of Cu2+ to Cu+ ion of the substrate Copper(II) 
sulfate pentahydrate. This reaction correlates to the amount of protein that is measured. 
A second reaction detects the Cu+ ions. Bicinchoninic acid is added which is able to form 
a chelate with Cu+ ion which can be detected by a purple color reaction. The BCA assay 
was read out at 540 nm with Victor2 1420 Multilabel Counter (Perkin Elmer). 
 
3.2.1.7. TRANSFECTION  
 
Transfection of cells was performed using lipofection, which is a chemical 
transfection method. Lipofectamine 2000 (Thermo scientific) was used as transfection 
reagent. During the transfection process, first the DNA is enveloped in a lipid shell. This 
lipid shell interacts with the cell membrane which leads to an integration of the DNA into 
the cell. 
For flow cytometry, HEK293T cells were plated at a concentration of 200.000 cells 
per ml in a 96 well Costar plate. The cells were transfected at a confluency of 70% with 5, 
10, 25, 50 or 100 ng of TACI-short or TACI-long plasmid. For the NFκB assay, HEK293T 
cells were plated at a concentration of 200.000 cells per ml in a 96 Costar plate and 
transfected at a confluency of 70% with Firefly-Luciferase (40 ng per well), Renilla-
Luciferase (40 ng per well) and BCMA (2.5 ng per well). For Co-Immunoprecipitation (Co-
IP) HEK293T cells were plated at a concentration of 300.000 cells per ml in a 10 cm dish. 
At a confluency of approximately 70% the cells were transfected with 10 µg of TACI-long, 
TACI-short and BCMA plasmids containing an N-terminal FLAG- and/or HA-tag. 48-72 h 
after transfection supernatants were harvested and cell lysates were obtained.  
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3.2.1.8. HARVEST OF SUPERNATANTS  
 
Different methods were applied to purify and separate proteins of interest from cell 
culture media. These methods were based on separation through centrifugation. For small 
volumes of up to 2 ml and supernatants from assays with HEK293T cells the proteins 
were harvested and centrifuged two times at 400 g at 4 °C for 7 min and one time for 
20.000 g at 4 °C for 30 min. The supernatants were stored at -20 °C. For bigger volumes 
like for example during the Co-IP assay the last step of centrifugation was carried out at 
4122 g for 30 min. During production of proteins with HEK293.EBNA cells the 
supernatants were harvested 72 h after transfection. The cell/supernatant mix was 
centrifuged once at 1200 rpm for 5 min at 4 °C. The supernatant was centrifuged a final 
time for 2500 rpm for 20 min at 4 °C followed by filtration with 0.22 µm MILLIPORE 
Stericup® Vacuum filter system (Merck Millipore). The supernatant was stored at 4 °C 
before application of the next steps. 
 
3.2.1.9. CELL LYSIS 
 
For NFκB assay the cells needed to be lysed to measure luciferase reaction. The 
cells were lysed with passive lysis buffer from Promega. The lysis buffer was diluted with 
distilled H2O in a ratio of 1:5. The cell culture media was removed and 50 µl of the lysis 
buffer was added. Everything was incubated for 10 min on a shaker at room temperature. 
For Co-IP the cells were washed with PBS and centrifuged once for 7 min at 400 g to 
eliminate cell culture medium residues. The cells were then lysed in 1.8 ml lysis buffer 
(Table 10) and stored for 30 min on ice. After cell lysis the lysates were centrifuged one 
time for 10 min at 14.000 rpm. The lysate aliquots were stored at -80 °C.  
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3.2.2. MOLECULAR CLONING 
3.2.2.1. AMPLIFICATION AND PURIFICATION OF THE INSERT 
 
In general, plasmids, genomic DNA or cDNA can be used as templates for 
polymerase chain reaction (PCR) during cloning. For this thesis, the plasmids TACI-short 
and TACI-long in PCDNA3.1 vector were used as template and these DNA sequences 
were amplified by PCR. The different steps of the PCR protocol used for all experiments 
are described in Table 24 and the different reagents of the PCR mixture in Table 23.  
The following general PCR mixture (Table 23) and standard protocol (Table 24) 
was used for all constructs: 
Table 23: PCR mixture 
Amount in µl Reagents Company 
31 H20 InvitrogenTM 
10 5x GC Puffer New England BioLabs, Inc. 
1 dNTPs (10 mM) Fermentas 
2.5 Reverse primer (10 µM) Metabion 
2.5 Forward primer (10 µM) Metabion 
1 Template (10 ng) - 
1.5 DMSO 100 % New England BioLabs, Inc. 
0.5 Phusion HF DNA Polymerase New England BioLabs, Inc. 
 
Table 24: Polymerase chain reaction protocol 
PCR step Temperature Time 
Denaturation 95 °C 30 s 
Primer Annealing 95 °C 15 s 
Elongation 72 °C 2 min 
 The first three steps were 
repeated 38 times 
 
Final Elongation 72 °C 7 min 
Final hold 4 °C Infinitely 
 
  
  
33 
 
Several tags and restriction sites were added to the DNA sequences during cloning 
(Table 13). For the creation of the sTACI-long and sTACI-short the signal peptide of the 
Ig kappa chain was added at the N-terminus of the proteins to ensure the secretion of the 
proteins. Moreover, a His6-tag consisting of the sequence for six consecutive histidines 
was added at the C-terminus for affinity purification with Nickel columns. The resulting 
DNA was inserted into vectors suitable for the destined application (Table 12). The 
plasmids for Co-IP were cloned with either a HA- or FLAG®-tag on the N-terminal side. 
The restriction enzymes (Table 14) and corresponding sites were chosen with the help of 
NEBcutter V2.0 and the sequences were added during PCR. After PCR the products were 
analyzed by agarose gel electrophoresis. After electrophoresis, the desired bands were 
cut. The DNA was purified with the QIAquickTMGel Extraction Kit (Qiagen GmbH) and 
stored at -20 °C. The concentration was measured with Nanodrop (Thermo scientific). 
 
3.2.2.2. DIGESTION OF INSERT AND VECTOR WITH RESTRICTION ENZYMES 
 
To generate sticky ends both the vector and insert DNA were incubated for 1-3 h 
with restriction enzymes at 37 °C (Table 14). In the last hour of digestion, the vector was 
dephosphorylated by adding calf intestine alkaline phosphatase (CIAP). The vector was 
loaded on a DNA gel and consecutively cut and purified using the QIAquickTMGel. 
MinElute columns (Qiagen GmbH) were used instead of the columns of the QIAquick Kit 
(Qiagen GmbH) to concentrate the sample to a smaller volume. The insert was purified 
using the MinElute® PCR Purification Kit (Qiagen GmbH). Both products were stored at 
– 20 °C before ligation. 
 
3.2.2.3. LIGATION 
 
Ligation was executed for 1 h at room temperature or overnight at 16 °C using the 
T4 DNA Ligase and the T4 DNA Ligase buffer containing ATP (New England BioLabs, 
Inc.). As a control one condition was comprised of only digested vector to test for self-
ligation.  
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3.2.2.4. TRANSFORMATION OF E. COLI, BACTERIAL CULTURE AND PLASMID 
DNA PURIFICATION 
 
After ligation the samples were transformed into E. coli (NEB® 5-alpha Competent 
E. coli) using heat shock transformation. The tube containing the frozen E. coli was thawed 
on ice for 10 min. Afterwards, around 100 ng of plasmid was added and mixed with the E. 
coli carefully. The E. coli and plasmid were then incubated for 30 min on ice, before heat 
shock was performed at 42 °C for 90 s. After Heat shock treatment the E. coli had a last 
cooling step on ice for 5 min. SOC medium was added to cooled down E. coli and the 
mixture was incubated for 1 h at 37 °C in a bacteria shaker at 250 rpm. Finally, the 
transformed bacteria were centrifuged at 4000 rpm for 5 min and dissolved in 100 µl 
Medium and then applied to preheated selection plates containing ampicillin. All vectors 
used contained ampicillin resistance. The plates were incubated overnight in a 37 °C 
bacteria incubator. The next day clones were picked and incubated for one day in 2 ml LB 
medium with addition of ampicillin in a ratio of 1:1000 to prevent unspecific growth of other 
bacteria. The following day DNA was purified using the QIAprep® Spin Miniprep Kit 
(Qiagen GmbH). 1 µg of DNA was digested with the identical restriction enzymes that 
were used to clone the construct for 1 h at 37 °C and then loaded on a DNA gel to check 
for positive clones. 
 
3.2.2.5. SEQUENCING 
 
After cloning the clones that were screened as positive, were analyzed and verified 
with Sanger sequencing by the LMU Sequencing Service. The method Big Dye v.3.1. 
cycle, clean and run was selected for the control of the sequence of the insert. 
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3.2.3. EXPRESSION OF PROTEINS AND CONSECUTIVE AFFINITY 
PURIFICATION  
3.2.3.1. PROTOCOL FOR TRANSFECTION  
 
HEK293.EBNA cells were transfected with Polyethyleneimine reagent (PEI, 
SIGMA-Aldrich® Co.LLC.) at a concentration of 1x106 cells/ml. First, the plasmid DNA-lipid 
complexes were prepared in Optipro Medium (GIBCO®). 1 µg of Plasmid was used per 
106 cells. PEI was applied at a concentration of 2 µg per 106 cells. After an incubation 
period of 20-30 min at room temperature the plasmid DNA-lipid complexes were added to 
the cells and then everything was placed into the Pro incubation shaker (Multitron) at 5% 
CO2 and 37 °C. 12-24 h later 5% Lactalbumin (SIGMA-Aldrich® Co.LLC.) was added to 
feed the cells.  
 
3.2.3.2. DIALYSIS AND FILTRATION OF SUPERNATANTS 
 
The supernatants were dialyzed with 8 kDa Spectra/Por®6 Dialysis Membrane 
(sTACI-long) or 3.5 kDa Spectra/Por®7 Dialysis Membrane (sTACI-short, sTACI-short (W-
68-154)). The supernatants were dialyzed at 4 °C for 24 h in 1x dialysis buffer (Table 9) 
while rotating on a magnetic stirrer. The buffer was exchanged every 8 h and in total three 
times. Finally, the supernatant was filtered with 0.45 µm MILLIPORE Stericup® Vacuum 
filter system (Merck Millipore) and stored at 4 °C before application to the column. 
 
3.2.3.3. AFFINITY PURIFICATION WITH HISTRAP COLUMNS  
 
Affinity purification or affinity chromatography was used to extract the recombinant 
proteins from the supernatant. The His6-tag that was added C-terminally to the soluble 
TACI isoforms during cloning was used for purification with HisTrap nickel columns 
(HisTrap HP (1 ml), GE Healthcare) on the ÄKTATM START (GE Healthcare). The His6-
tag was added as it can form a chelate with the nickel ions of the used columns. Later 
Imidazole was used to elute the specifically bound proteins. Imidazole competes with 
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His6-tags for the binding to Nickel. Increasing amounts of Imidazole can remove the 
proteins and clean the column. 
Firstly, the HisTrap column was washed with Millipore H2O to remove the storage 
buffer from the column (20% ethanol). Then 1x dialysis buffer (Table 9) was added to 
equilibrate the column to the sample milieu. Depending on the volume of the supernatant, 
the column was either directly loaded with the ÄKTA STARTTM for small volumes or 
overnight with the LKB Pump P-1 Peristaltic Pump (Pharmacia) in the cold room at 4 °C 
for high volumes. After sample application one last washing step was carried out with 1x 
dialysis buffer to get rid of unspecifically bound proteins. The elution step was performed 
with an Imidazole gradient ranging from 0.01–1 M. Eluted proteins were dialyzed against 
the storage buffer (Table 9) with 3,500 MWCO Slide-A-Lyzer Dialysis cassettes (Thermo 
scientific) to avoid protein aggregation upon freezing. 
 
3.2.4. CHARACTERIZATION OF THE PROTEINS 
3.2.4.1. PNGASE F DIGESTION AND TEST FOR DIVALENT ION-HIS6-TAG 
INTERACTION  
 
Glycosylation of the proteins was tested with the enzyme PNGase F (New England 
BioLabs, Inc.). PNGase F is an amidase able to cleave N-linked sugars from glycoproteins 
and glycopeptides when Asn-oligosaccharides are present (148). The sTACI isoforms 
were incubated with glycoprotein denaturation buffer and then denatured for 10 min at 
100 °C. The mixture was chilled on ice and then centrifuged for 10 s. Next, Glycobuffer, 
10% NP-40 and distilled water were added. In the final step PNGase F was added and 
incubated for 1 h at 37 °C. Controls consisted of several conditions with and without 
PNGase F and non-treated protein that only followed the temperature regime. hMOG 
which is known to be N-linked glycosylated was used as a positive control. Western blot 
was used to analyze the results.  
His6-tagged proteins are susceptible to aggregation caused by divalent metals 
such as nickel and cobalt. During purification this mechanism is used to purify the 
recombinant proteins from other proteins that are co-produced during protein synthesis. 
Divalent Nickel ions sometimes can be washed of the purification column and lead to 
protein aggregation through building chelates with His6-tag purified proteins. To exclude 
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an artificial interaction of the His6-tags of the recombinant proteins` with eluted nickel ions 
100 mM EDTA with a pH of 7.5 was added to the proteins and incubated for 1-2 h at room 
temperature in order to sequester possible nickel ions. Several conditions with or without 
DTT and with or without EDTA were tested. 
 
3.2.4.2. MASS SPECTROMETRY AND N-TERMINAL SEQUENCING 
 
Mass spectrometry can be used to identify and to provide sequence information of 
different protein bands after gel-electrophoresis. Therefore, the bands of interest were 
accurately cut from the gel, stored in distilled water and then processed by Reinhard 
Mentele (Institute of Clinical Neuroimmunology, LMU) at the MPI and the Biomedical 
Center (BMC) of the LMU. Trypsin digestion was used for all affinity purified proteins. The 
N-terminal part of the proteins can be analyzed by N-terminal sequencing. After running 
the proteins through gel electrophoresis to separate the different fractions by size the 
proteins were transferred semidry to a polyvinylidene difluoride (PVDF) membrane. The 
membrane was consecutively stained for 3-4 min with Coomassie brilliant blue, destained 
for 10 min with destain buffer and washed 10 min with distilled water. After cutting the 
bands of interest, the bands were air dried. The analysis was carried out by Reinhard 
Mentele at the MPI and the BMC of the LMU. 
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3.2.4.3. SIZE EXCLUSION CHROMATOGRAPHY  
 
Size Exclusion Chromatography (SEC/Gel-filtration) was used to determine the 
molecular weight of both sTACI isoforms and to figure out whether the proteins form 
oligomers. Additionally, it was used to obtain the different fractions of the sTACI isoforms 
by size exclusion. SEC was carried out in collaboration with Prof. Michaela Smolle 
(Department of Physiological Chemistry, LMU). The columns for gel-filtration are filled with 
gel beads that are characterized by holes and an internal gel matrix. Big proteins cannot 
enter the beads and thus run through the column with high velocity. This fraction 
represents the void volume. Consequently, proteins can be separated by size as small 
proteins need longer to run through the column than bigger proteins (Figure 8).  
 
 
Figure 8: Principle of size exclusion chromatography 
Proteins run through a column filled with Gel beads (a-d). Holes and an internal Gel matrix 
characterize these Gel beads. While running through the column bigger proteins (blue) which 
cannot enter the Gel matrix run through the column without delay and are eluted earlier than 
smaller proteins (red) who have to go through the holes of the Gel beads and Gel matrix. (b-e) 
Proteins can be divided by size and separated in different fractions through SEC as indicated in 
the tubes below. (b-e) A chromatogram shows the different fractions. (e) Picture taken from (149) 
page 139. 
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First, the proteins were concentrated to approximately 3-10 mg/ml with Amicon® 
Ultra centrifugal filters (Ultracel® - 3K). Before application to the column the concentrated 
proteins were centrifuged at 14 000 rpm for 5 min at 4 °C to decrease the amount of 
aggregated protein. The column (Table 7) was equilibrated with exchange buffer over 
night with the ÄKTATM PURE (GE Healthcare) at 4 °C before loading approximately 500 
µl of concentrated protein. During the run, the equilibrated machine measured the volume 
of buffer that went through its system together with data concerning the UV-absorbance 
of the fluid. The volume was important for later calculations of the MW. For this calculation 
the elution volume of each fraction was needed. Finally, the separated fractions were 
collected and then further analyzed by SDS-PAGE. After the run the column was cleaned 
wit 0.5 M NaOH and the ÄKTATM PURE system and columns were stored in H2O with 
0.01% sodium azide. 
Additionally, a series of standard proteins was run under the identical conditions. 
The elution volume of each protein was used to calculate the partition coefficient (Kav) 
with the following equation (Equation 3). 
 
 
 =   	 −    −        
Equation 3 : Partition coefficient 
 
(Vo = column void volume, Ve = elution volume, Vc = geometric column volume, Kav = partition coefficient)  
The calibration curve was then determined by the Kav of the standard proteins on 
the x-axis and the given logarithm of MW of the standard proteins on the y-axis. Size 
standard and Void volume were compiled using the Low Molecular Weight (LMW) Gel-
filtration Calibration Kit (Table 6). Blue Dextran was used to determine the void volume. 
 
  
  
40 
 
3.2.4.4. STATIC LIGHT SCATTER COUPLED TO SIZE EXCLUSION 
CHROMATOGRAPHY  
 
Another method to determine the molecular weight of proteins is static light scatter 
(SLS) coupled to SEC. Molecules and Particles can be characterized by the properties 
they show when they are hit with light. Molecules absorb the energy from the light and 
then reemit the energy in all directions (Figure 9). All SEC and SLS/SEC experiments 
were carried out in collaboration with Prof. Michaela Smolle (Department of Physiological 
Chemistry, Ludwig-Maximilian University) at the LMU BioPhysics Core Facility. 
 
 
 
Figure 9: Principle of static light scatter detection 
Directly after gel-filtration proteins run through the flow cell. Light from the laser enters the cell and 
is detected at 90° (RALS = Right-angle light scattering) and at a low angle for example 7° (LALS 
= low-angle light scattering). Figure adapted from (150). 
 
The Rayleigh equation combines the size, MW and intensity of the scattered light 
and is the foundation of static light scatter analysis (Equation 4). The refractive index 
detector (RI) measures the concentration of proteins.  
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The Rayleigh equation is defined as: 
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Equation 4: Equation of Rayleigh 
 
(K = Optical constant, C = Concentration, M = Molecular weight, Rθ = Rayleigh ratio, A2 = 2nd Virial 
coefficient, P(θ) = Shape (or form) factor) 
 
 With Optical constant K defined as: 
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Equation 5: Optical constant K 
(λo= laser wavelength, NA= Avogadro’s number, no =Solvent RI, dn/dc = differential RI increment)  
 
With Rayleigh ratio Rθ defined as: 
 
67 = 841
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Equation 6: Rayleigh ratio Rθ 
 
(IA = intensity of analyte (sample I – solvent I), no = solvent RI,IT = intensity of standard (toluene),nT = 
standard (toluene) RI,RT = Rayleigh ratio of standard (toluene)) 
 
 
 
With Shape factor Pθ defined as:  
 
1
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Equation 7: Shape factor Pθ 
 
(n0 = refractive index of the solvent, λ0 = laser wavelength in a vacuum, Rg = Radius of gyration, θ = 
Measurement angle) 
 
 
After acquiring all data - including the intensity of the scattered light- the MW of the 
sample can be calculated. The sTACI-long and sTACI-short proteins were applied to a 
Superdex 200 Increase 10/300 GL column and run through the ÄKTA PURE® to separate 
the different fractions by SEC. The same concentration that had been used previously for 
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SEC was added to the column, after determining and verifying the optimal amount for SLS 
analysis with a dilution series of bovine serum albumin fraction V (SIGMA-Aldrich® 
Co.LLC.). The range was about 1-3 mg/ml. The separated fractions were directly run 
through the OMNISEC REVEAL (Malvern) instead of being eluted in contrast to SEC. The 
whole OMNISEC REVEAL system was equilibrated prior with 1x storage buffer to the 
sample milieu. BSA was used to equilibrate the static light scatter system as standard 
protein for the later MW calculations. Some of the proteins from the Low Molecular Weight 
(LMW) Gel-filtration Calibration Kit were used as a positive control (Table 6).  
 
3.2.4.5. CO-IMMUNOPRECIPITATION 
 
Immunoprecipitation (IP) is used to concentrate and isolate antigens from a 
solution with the help of antibodies. Co-Immunoprecipitation (Co-IP) is an advancement 
of this method. Co-IP is used to analyze protein-protein interactions with the use of a 
target protein. The target protein is isolated and concentrated through IP. Proteins that 
interact with the target protein and form complexes can be detected after IP.  
FLAG®-tagged beads (ANTI-FLAG® M2 Magnetic Beads, Sigma Aldrich) were 
resuspended and separated into 1.5 ml tubes. To remove the storage buffer the beads 
were washed five times with TBS Buffer using a magnetic separator (Table 10). The cell-
lysates and supernatants were added sequentially in 1 ml steps and each time incubated 
for 1.5 h or overnight at 4 °C while rotating and shaking. Different amounts of protein were 
loaded between the supernatant and cell-lysates. Within the group of supernatants and 
the group of cell-lysates every condition had the same amount of protein applied. The 
supernatants were separated from the beads with a magnetic separator at the end of 
every incubation period and discarded. After application of the sample, the beads were 
washed five times with TBS Buffer to eliminate proteins that where not directly bound to 
the beads. The elution was done under acidic conditions by incubation with glycine (1 M 
pH 3) for 20 min at 56 °C. To preserve activity of the proteins the eluates were neutralized 
with Tris Buffer (1 M Ph 9) (Table 10). (Figure 10) 
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Figure 10: Principle of Co-Immunoprecipitation 
FLAG®-coated beads are used to capture FLAG®-tagged target proteins. The TACI isoforms either have a 
FLAG®-(green dot) or HA-tag (blue square) added to the N-terminal side. The Anti-HA ELISA after 
immunoprecipitation shows if proteins interact and if the HA-tagged proteins were immunoprecipitated. 
Figure adapted from (93). 
 
The IP and pre IP samples were tested with TACI, BCMA and anti-FLAG® ELISA 
as a control for the transfection and success of IP. The Anti-FLAG® ELISA was used to 
test the IP. The plate was coated with Anti-FLAG® M2 Antibody (dissolved in PBS at a 
concentration of 5 µg/ml) overnight at 4 °C (Table 20). The interaction was tested with 
anti-HA ELISA. The plates got coated with a HA antibody as capture antibody (5 µg/ml) 
and incubated over night at 4 °C (Table 20). Then the TACI DUO set or BCMA ELISA 
protocol was followed starting with the detection antibody step.  
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3.2.5. FUNCTIONAL TESTS 
3.2.5.1. BINDING ELISA 
  
A sandwich ELISA called binding ELISA was used to determine the affinity of the 
sTACI proteins to the Ligands BAFF and APRIL (Figure 11). The affinity of the proteins 
for BAFF and APRIL was compared by calculating the equilibrium dissociation constant 
(KD) value. Generally, a small KD indicates a high affinity of a protein to its ligand.  
 
Figure 11: Principle of binding ELISA 
The binding ELISA is a sandwich ELISA. The plate was coated with anti-FLAG antibody over night 
at 4 °C. The first incubation step is with a FLAG-tagged Ligand. The next step consists of 
application of sTACI-long, sTACI-short or TACI-Fc. To assess whether sTACI was able to bind to 
the FLAG-tagged Ligand the detection antibody of the TACI Duo set ELISA was used. The rest of 
the assay followed the normal TACI Duo set ELISA protocol. Figure was taken from (93).  
 
For the Binding ELISA the plate was coated with Anti-FLAG® M2 Antibody 
(dissolved in PBS at a concentration of 5 µg/ml) overnight at 4 °C. After three washing 
steps the plate was blocked with Reagent Diluent (Table 10) for at least 1 h at room 
temperature. Then, BAFF-FLAG® (R&D Systems) or APRIL-FLAG® (mouse: AdipoGen or 
human: SIGMA-Aldrich® Co.LLC) were added in a concentration of 100 ng/ml and 
incubated for 2 h at room temperature. A dilution series of both sTACI isoforms was 
prepared, added to the plate and then incubated for 2 h at room temperature. After 
application of the dilution series, the TACI Duoset ELISA protocol was followed.  
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3.2.5.2. TEST OF DECOY FUNCTION WITH NFκB ASSAY 
 
Ligand-receptor interactions can be assessed with reporter cell assays, like the 
NFκB assay. In NFκB assay activation of a receptor leads to intracellular NFκB pathway 
induction which can be detected, in this case with luciferase (151) (Figure 12). 
The ability of a soluble receptor to decrease luciferase activiation by disabling the 
ligand from binding to the cell can be measured in the form of an inhibition assay. The half 
maximal inhibitory concentration (IC50), a value indicating the potency of a decoy receptor, 
was determined. Small IC50 values indicate good inhibition function of the substrate. The 
IC50 gives the concentration of a substrate that leads to a 50% decrease of the normal 
activation signal.  
 
Figure 12: Principle of NFκB assay 
After extracellular stimulation an intracellular cascade leads to synthesis of a TRE promoter 
dependent reporter protein. The reporter protein can be visualized by adding for example Luciferin 
and ATP if the reporter protein is luciferase. Adapted from (152). 
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In this assay NFκB activation was detected with the Firefly-Luciferase which is 
under control of NFκB transcriptional response element (TRE). In order to control for 
varying cell numbers, active Renilla-Luciferase was co-transfected constitutively, which is 
under control of the CMV promoter. To detect the reporter proteins a substrate mix of 
Luciferin and ATP (Biozym Scientific GmbH) was used for Firefly-Luciferase and 
coelenterazine (Promega) for Renilla-Luciferase. Full-length BCMA was used as a 
receptor for the ligands. 
A dilutions series of sTACI was prepared 8 h after transfection of HEK293T cells 
with BCMA, Renilla-luciferase and Firefly-luciferase. APRIL (AdipoGen) or BAFF (R&D 
Systems) were added to the dilution series in a concentration of 100 ng/ml. The 
sTACI/ligand mixture was incubated in a heat shaker at 37 °C at 300 rpm for 15-30 min 
and then added to the transfected cells while discarding the old medium. Finally, 17 h later 
the NFκB activation was measured after lysing the cells. The lysed cells were pipetted into 
Corning™ 96-Well Solid White Polystyrene Microplates and the substrate mix for either 
Firefly-Luciferase or Renilla-Luciferase was added. Afterwards, luminescence was 
detected and read out with Perkin Elmer Victor2 1420 Multilabel Counter. 
 
3.2.5.3. FLOW CYTOMETRY ASSAYS 
 
Flow cytometry can be used to quantify and characterize the phenotype of cells. 
Cells are run cell by cell in a liquid medium by a laser to generate information about the 
size and complexity of the cells by assessing the scattering of light around them. The 
forward scatter generates information about the size and volume of the cell. The sideward 
scatter generates information about the granularity. Furthermore, the cells were 
characterized with fluorescence labeled antibodies. These antibodies recognize either a 
specific surface structure (direct detection) or an already bound antibody (indirect 
detection). The surface structures in this thesis were indirectly labeled with Anti-TACI or 
Anti-FLAG® antibodies, before detection with a PE labeled antibody (Table 21). When hit 
with a laser, a fluorescence signal is emitted after excitation of the fluorochrome of the 
antibody and can be detected by the flow cytometer. Several fluorochromes can be 
chosen for one measurement if the wavelength spectra of the emission differ. For this 
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thesis, only one fluorochrome was used for the characterization of all cells (PE) together 
with an indicator (TO-PRO®-3 Iodide (Invitrogen)) of dead cells (Table 22). The BD 
FACSVerseTM flow cytometer (BD Biosciences) was used to generate the data in 
combination with the FlowJo software (BD Biosciences) which was used to analyze all 
data. Flow cytometry was used to assess the expression of membrane-bound TACI 
proteins after transfection of HEK293T cells and to test the membrane-bound binding 
properties of TACI isoforms to BAFF and APRIL (Figure 13). 
 
 
Figure 13: Principle of Binding flow cytometry 
 
24 h after transfection with TACI-long or TACI-short the cells were either directly 
tested for surface expression or incubated for 3 h with BAFF- or APRIL-FLAG® to analyze 
the binding of the surface TACI isoforms to BAFF and APRIL. BAFF- or APRIL-FLAG® 
was added at a concentration of 100 ng/ml. The cells were transferred onto flow cytometry 
plates. All centrifugation steps were executed at 400 g for 5 min at 4 °C. The cells were 
centrifuged and the supernatants discarded. To remove the medium, two further washing 
steps with PBS containing 1% BSA were applied. The primary antibody was added and 
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incubated for 30 min on ice protected from light at a concentration of 1 µg/ml (for both 
primary antibodies) (Table 21). Three further washing steps were executed to wash the 
primary antibody off and the secondary antibody (Table 21) was added and incubated for 
30 min at 4 °C at a concentration of 5 µg/ml while protected from light. The secondary Ab 
was then removed with three washing steps. TO-PRO®-3 Iodide (Invitrogen) (diluted 
1/4000 in PBS) was used to assess the amount of dead cells.  
 
3.2.6. STATISTICAL ANALYSIS 
 
Prism Software (GraphPad) was used for all statistical and analytical analysis in 
this thesis with the only exception of the determination of MW by SEC. There, Excel was 
used to determine the calibration graph and MW values resulting from the Kav of the 
eluted proteins. Statistical significance for the expression assay, binding ELISA, and NFκB 
reporter assay was assessed using unpaired two-tailed t-test with or without Welch’s 
correction or normal one way ANOVA. The KD and IC50 were calculated using specific 
programs that are already designed for these applications as part of the Prism Software. 
For multiple results as part of an experiment the arithmetic mean was calculated and is 
shown in the graphs as the main value. To show the varying distribution of values around 
the arithmetic mean in the graphs, the standard error of the mean (SEM) was determined.  
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4. RESULTS 
4.1. CHARACTERIZATION OF SOLUBLE TACI ISOFORMS 
4.1.1. CLONING AND RECOMBINANT PRODUCTION OF sTACI-LONG, 
sTACI-SHORT AND sTACI-SHORT (W-68-154) 
 
First, the plasmids for sTACI-long and sTACI-short were cloned (Figure 15). The 
sequence was chosen according to two different studies (93, 146). sTACI-long has two 
cysteine rich domains (CRDs) (CRD1+CRD2), while sTACI-short has only one (CRD2) 
(Figure 14). 
 
Figure 14: Illustration of different TACI constructs 
sTACI-long, sTACI-short and sTACI-short (W-68-154) were produced recombinantly. The Fc 
constructs were provided by Pascal Schneider (University of Lausanne, Switzerland). The 
numbers below the name of the construct indicate the amino acid sequence of each construct. 
The illustration next to it shows the CRDs of each construct, the amino acid sequence and the 
addition of Fc if present. CRD1+CRD2-Fc-a, which is an atacicept analog, was designed to have 
mutations in its Fc part so that FcyR binding and complement activation is prevented. The 
difference is illustrated by a light blue layered Fc for CRD1+CRD2-Fc-a in comparison to the brown 
layered Fc of the other TACI-Fc. The illustrations are adapted from (122, 146). 
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Previous constructs of TACI from other groups were missing the first 20 to 30 amino 
acids of the sequence on the N-terminal side and started directly at the CRDs (140). An 
atacicept analog variant (CRD1+CRD2-Fc-a) and other TACI-Fc constructs were provided 
by Pascal Schneider for this thesis (University of Lausanne, Switzerland). sTACI-short 
(W-68-154) which was designed to miss the first 20 amino acids on the N-terminal was 
developed to test if these 20 amino acids influence the binding affinity. The resulting 
protein sequences of sTACI-long, sTACI-short, and sTACI-short (W-68-154) are 
illustrated in Figure 14. The sequences of the TACI-Fc constructs are shown in 
comparison. 
During the cloning process a His6-tag was added C-terminal for later affinity 
purification. The constructs contained the signal peptide of Ig-kappa N-terminal to ensure 
protein secretion. The resulting plasmids for sTACI-long and sTACI-short are depicted in 
Figure 15.  
 
 
Figure 15: Plasmids of sTACI-long (A) and sTACI-short (B) 
 
All three sTACI constructs were expressed in eukaryotic HEK293.EBNA cells and 
then affinity purified with HisTrap columns and a gradient using Imidazole essentially as 
published (153). The signal peptide of Ig kappa chain was cleaved intracellularly before 
secretion. The different steps of protein purification are indicated in small letters above 
the UV chromatogram in Figure 16 A. After purification, the eluted protein fractions were 
analyzed by Coomassie stained SDS-PAGE. Examples of after purification screenings of 
sTACI-long, sTACI-short, and sTACI-short (W-68-154) are shown in Figure 16 B, C, and 
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D. Fractions from fourteen purifications were pooled together for sTACI-long, fractions 
from five purifications for sTACI-short and fractions from three purifications for sTACI-
short (W-68-154). The results from functional tests are not dependent on a single 
purification. The pooled samples were dialyzed against storage buffer and stored at -80 
°C.  
 
  
Figure 16: Affinity purification of sTACI variants 
(A) UV chromatogram of a purification of sTACI-short (W-68-154). The different steps of affinity 
purification consist of the washing and equilibration of the column (a), the loading of the protein 
(b), an additional washing step to remove unspecifically bound proteins (c) and a final elution of 
the protein from the column (d). (B-D) Coomassie staining of SDS-PAGE of eluted fractions from 
affinity purification from 1L Hek293.EBNA cells (B) for sTACI-long, (C) sTACI-short and (D) sTACI-
short (W-68-154). The numbers 1-6 indicate different fractions of the eluted proteins. 
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4.1.2. OLIGOMERIZATION OF sTACI  
 
sTACI-long (Figure 16 B) and sTACI-short (W-68-154) (Figure 16 D) appeared at 
molecular weights suggesting that the preparations contain in addition to the monomeric 
form also oligomers. sTACI-short (Figure 16 C) showed these signs of oligomerization 
only in high amount of purified protein. For sTACI-long, the reducing agent DTT, but not 
heat denaturation for 5 min at 95 °C, was able to break the bond or denature the protein 
so that it appeared in its monomeric state (Figure 17 A). Furthermore, DTT was added to 
sTACI-short to study whether the amount of sTACI-short would increase as possible 
higher molecular oligomers would break. sTACI-long was used as positive control for DTT 
treatment and as a test if reduced and non-reduced sTACI-long could be detected by the 
same antibody in Western blot (Figure 17 B). DTT treatment had no effect on sTACI-short 
(Figure 17 B), while the dimers of sTACI-long turned onto monomers. Both sTACI-long 
monomers and dimers could be detected by our Western blot detection antibody. sTACI-
long and sTACI-short detection decreased after DTT treatment (Figure 17 B).  
 
 
Figure 17: Analysis of stability of oligomerization of sTACI-long and sTACI-short 
(A) sTACI-long was treated with heat-denaturation at 95 °C for 5 min, DTT or both, and compared 
to non-treated sTACI-long. Coomassie stained SDS-PAGE was used for analysis. (B) sTACI-long 
and sTACI-short were either analyzed without any treatment or with heat denaturation and DTT 
by Western blot using the mAb anti-TACI TACI/TNFRSF13B (Clone 165609).  
It was previously proposed that divalent-ion/His6-tag interactions may cause 
oligomerization in recombinant purified proteins (84). Nickel ions that dissolved from the 
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purification column and passed to the eluted fragment, could cause artificial aggregates. 
EDTA is highly potent at forming chelates with divalent ions. To further investigate these 
findings, an interaction between the His6-tag of the purified sTACI-short (W-68-154) and 
possible eluted Nickel ions from the purification column was tested by EDTA assay. This 
assay was performed with sTACI-short (W-68-154) because we observed several higher 
oligomers for sTACI-short (W-68-154) (Figure 16 C) in Coomassie stained SDS-PAGE. 
sTACI-short (W-68-154) did not form new aggregates after higher molecular weight bonds 
were broken by DTT (Figure 18). There was no effect of EDTA on oligomerization in non-
reducing conditions. After reduction with DTT the protein stayed in its monomeric state. 
Heat denaturation alone had no impact on oligomerization similar to sTACI-long.  
 
 
Figure 18: Analysis for possible artificial oligomerization of sTACI-short (W-68-154) 
Coomassie stained SDS-PAGE of sTACI-short (W-68-154). DTT was added to put sTACI-short 
(W-68-154) into its monomeric state. EDTA was then applied to sequester possible Nickel ions 
that were eluted from the HisTrap column. sTACI was incubated with DTT and/or EDTA for 1-2 h 
at room temperature to give Nickel ions the time to rebuild high molecular aggregates with the 
His6-tags of sTACI-short (W-68-154).  
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4.1.3. N-LINKED GLYCOSYLATION OF sTACI-LONG AND sTACI-SHORT 
 
N-linked glycosylation was predicted for both sTACI isoforms at amino acid 128 (N) 
by Uniprot (28). The sequence pattern N-X-T/S indicates N-linked glycosylation sites 
which are glycosylated with a probability around 50% (154-157). This sequence is one 
time present within the sTACI sequence for both isoforms as illustrated in (Figure 20). 
Posttranslational modifications such as sugars can disturb later evaluation of the proteins 
by mass spectrometry. Therefore and additionally to test the nature of the secreted 
proteins, a PNGase F assay was performed. PNGase F is an amidase that can cleave N-
linked oligosaccharides from proteins (148). As a positive control, hMOG, which is known 
to be N-linked glycosylated, was used (158). PNGase F reduced the MW of hMOG, but 
not of TACI-long or TACI-short (Figure 19). Thus, our sTACI-long and sTACI-short were 
not N-linked glycosylated.  
 
 
Figure 19: Analysis of glycosylation of sTACI-long, sTACI-short and hMOG 
sTACI-long and sTACI-short (A) and as a control hMOG (B) were treated with the enzyme PNGase 
F as indicated. Subsequently, the proteins were separated by SDS-PAGE and detected by 
Western blot using the mAb anti-TACI TACI/TNFRSF13B (Clone 165609) for TACI (A) and murine 
anti-MOG antibody 8.18.c5 (B).  
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4.1.4. MASS SPECTROMETRY AND N-TERMINAL SEQUENCING OF 
sTACI-LONG AND sTACI-SHORT 
 
Analysis of the recombinant proteins sTACI-long and sTACI-short by gel 
electrophoresis showed that both recombinant proteins appeared at the expected 
molecular weight (Figure 20 A). We noted that they did not appear as a single band, but 
rather as a double band. Additionally a smaller band appeared in sTACI-short 
preparations that could only be detected in Coomassie staining (Figure 20 A, right part). 
To clarify the identity of the different bands in our sTACI preparations mass-spectrometry 
and N-terminal sequencing were applied (Figure 20 B-D). This showed that all closely 
related bands were TACI.  
The upper bands of both isoforms (sTACI-long (a) and sTACI-short (c)) largely 
consisted of the whole protein (Figure 20 B-C). The lower bands missed the first 15 amino 
acids of the sequence on the N-terminal side. The 7 kDa form of sTACI-short was missing 
the first 15 amino acids of the sequence on the N-terminal side and additionally 19 amino 
acids on the C-terminal side (Figure 20 D). This suggests that the 7 kDa form might 
represent a degradation-product. Full length sTACI-short is later on referred to as sTACI-
short (1-20-W-68-154) and the 7 kDa variant as sTACI-short (16-20-W-68-135). The 
changes of sequence in sTACI-short (16-20-W-68-135) did not affect the CRD2 which is 
responsible for high affinity binding to the ligands BAFF and APRIL. Thus, these changes 
were not predicted to have an effect on the functionality of the protein within the 
BAFF/APRIL system.  
Several additional sequences were found while analyzing the N-terminal side of 
sTACI-long and sTACI-short (Figure 20 B-D). These variants of the N-terminus could 
largely be attributed to Furin cleavage. Furin is a major protease of the secretory pathway 
primarily located at the Golgi apparatus. Furin cleaves proteins after basic residues in 
motifs such as Arg-X-X-Arg, Arg-X-Lys/Arg-Arg or Lys/Arg-X-X-X-Lys/Arg-Arg (159). Such 
motifs are also present two times within the first 20 amino acids of the sequence of TACI 
on the N-terminal side (Figure 20). The additional N-terminal sequence variant of sTACI-
short could not be attributed to a specific protease yet.  
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Figure 20: Analysis of recombinant sTACI-long and sTACI-short by Western blot, 
Coomassie staining, N-terminal sequencing and mass spectrometry 
(A) sTACI-long (lane 1 and 3) and sTACI-short (lanes 2 and 4) were separated by SDS-PAGE 
and visualized by Western blot (left) or Coomassie staining (right). Band e could not be detected 
by Western blot (A). The bands indicated with a-e were cut and as displayed in (B-D), analyzed 
by N-terminal sequencing and after digestion with trypsin by mass-spectrometry (Reinhard 
Mentele). The amino acid sequence obtained by mass-spectrometry is given in black letters. The 
parts of TACI-long (A) and TACI-short (C, D) that were not detected by mass-spectrometry are 
given as red letters. The sequences most frequently obtained by N-terminal sequencing of the 
bands a-e are indicated with a green line. Cleavage points that can be attributed to Furin are 
indicated by an orange line and the number next to it shows the canonical sequence which is the 
basis for that particular cleavage. An additional N-terminus of a variant included in sTACI-short is 
indicated by a blue line. The light blue line indicates a predicted site for N-linked glycosylation.  
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4.1.5. SIZE EXCLUSION CHROMATOGRAPHY OF sTACI-LONG AND 
sTACI-SHORT 
 
Size exclusion chromatography (SEC/gel-filtration) was performed to further 
assess the oligomerization of sTACI-long and sTACI-short. The proteins were run through 
a column that contained a specific matrix which led to separation of each fraction 
according to size. Directly after the column the different fractions were detected by a UV 
spectrometer (Figure 21 A+B) and analyzed for separation by Coomassie stained SDS-
PAGE (Figure 21 C+D).  
 
 
Figure 21: Analysis of Oligomerization of sTACI-long and sTACI-short by SEC 
(A and B) sTACI-long (A) and sTACI-short (B) were analyzed by SEC and the resulting UV-
chromatograms are shown. The sTACI-long monomer is indicated by the inscription 1x and a 
purple layer and the sTACI-long dimer by 2x and a green layer (A). The void volume is represented 
by the first peak in both UV-chromatograms (A and B). sTACI-short (1-20-W-68-154) is indicated 
by the inscription (1-20-W-68-154) and a red layer and sTACI-short (16-20-W-68-135) by (16-20-
W-68-135) and an orange layer. The higher grade oligomers of sTACI-short are represented by 
S1-S4. (C and D) Coomassie stained SDS-PAGE of separated fractions after SEC of sTACI-long 
(C) and sTACI-short (D). The numbers below the x-axis in A and B indicate the fractions that were 
used for Coomassie staining in C and D. 
  
58 
 
sTACI-long appeared as a dimer and monomer in SEC (Figure 21 A). sTACI-short 
showed in addition to the monomeric sTACI-short (1-20-W-68-154) and sTACI-short (16-
20-W-68-135) small amounts of higher oligomers (Figure 21 B). Furthermore, the dimer 
and the monomer of sTACI-long and sTACI-short (1-20-W-68-154), sTACI-short (16-20-
W-68-135), and sTACI-short higher oligomers were separated of by SEC (Figure 21 
C+D). Most fractions could be separated accurately except for the sTACI-long dimer. 
Pooled fractions of the sTACI-long dimer were a mixture of dimer and monomer with an 
enrichment of the dimer fraction. These fractions were pooled and stored at -80 °C for 
later used for functional evaluation. 
Determination of the MW of the fractions S1-S4 of sTACI-short with SEC standard 
curve (data not shown) showed that these fractions most likely represent higher oligomers 
of sTACI-short (S4 = 3x sTACI-short, S3 = 6x sTACI-short, S2 = 9x, sTACI-short, S1 = 
12x sTACI-short). This view is also supported by ELISA and Coomassie stained SDS-
PAGE. The fractions were concentrated and shown to be TACI by hTACI ELISA (Figure 
22 A). Additionally, the concentrated fraction of S3 could be detected at the expected MW 
weight of 6x sTACI-short (around 70 kDa) in Coomassie stained SDS-PAGE (Figure 22 
B). These findings suggest that sTACI-short oligomerizes in small amounts. This is in 
concordance with our sTACI-short variant sTACI-short (W-68-154) that showed signs of 
higher molecular weight oligomers in Coomassie stained SDS-PAGE directly after affinity 
purification (Figure 18).  
 
Figure 22: Analysis of small SEC peaks (S1-S4) of sTACI-short 
(A) The fractions S1-S4 (see Figure 21 (B)) were concentrated and then measured by hTACI 
ELISA. (B) The concentrated samples were applied to Coomassie stained SDS-PAGE.  
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4.1.6. DETERMINATION OF MOLECULAR WEIGHT OF sTACI-LONG 
AND sTACI-SHORT 
 
The MW of the monomer of sTACI-long was calculated at 17.4 kDa and sTACI-
short (1-20-W-68-154) at 12.2 kDa by an online tool (Expasy). The dimer of sTACI-long 
was approximated through Coomassie stained SDS-PAGE around 34 kDa and sTACI-
short (16-20-W-68-135) at 7 kDa.  
At first, we determined the MW of both sTACI isoforms by generating a SEC 
standard curve (Figure 23). With this method the sTACI-long monomer was calculated at 
29.9 kDa and the sTACI-long dimer at 58.3 kDa. sTACI-short (1-20-W-68-154) was 
determined at 19.9 kDa and sTACI-short (16-20-W-68-135) at 9.2 kDa.  
 
 
Figure 23: Molecular weight determination using SEC standard curve 
Proteins of known molecular weights were used to generate a standard curve for the HiLoad 16/60 
Superdex 75 pg column. The standard curve was generated by plotting the MW in logarithmic 
scale on the y-axis against the KaV on the x-axis. The KaV of the different sTACI fractions are 
indicated by dots on the x-axis. 
 
The substantial differences between the results from MW determined by SEC 
(Figure 23) and the predicted and observed MW by Coomassie stained SDS-PAGE, led 
to the decision to analyze the proteins further with a SLS/SEC system (Figure 24). With 
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our SLS/SEC system we were able to analyze our proteins with size exclusion 
chromatography (SEC) coupled to static light scatter (SLS). Before application of our own 
samples the system had to be optimized and a dilution series with human albumin fraction 
V was applied to find out the proper amount of protein that needs to be used. We found 
out that 1-3 mg/ml of sample led to optimal results (data not shown). Some proteins from 
the standard curve were used as positive control. As an example Conalbumin with a given 
MW of 75 kDa and Ribonuclease A with a given MW of 13.7 kDa were chosen. SLS 
calculated Conalbumin at 76.3 kDa and Ribonuclease A at 14.3 kDa (Figure 24). 
 
 
Figure 24: Molecular weight determination using SLS/SEC 
After SEC the separated fractions were directly analyzed with SLS. (A-C) sTACI-long (A), sTACI-
short (B) and Conalbumin together with Ribonuclease A (C) were run through the SLS/SEC 
system. The refractive index (concentration) is put on the y1-axis, the MW on the y2-axis and the 
retention volume on the x-axis. 
 
The calculated MW values for sTACI-long and sTACI-short that were derived by 
SLS/SEC analysis were close to the predicted and observed MW values. The MW of the 
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sTACI-long dimer was calculated at 30.2 kDa and of the sTACI-long monomer at 18.3 
kDa. For sTACI-short (1-20-W-68-154) the MW was determined at 12.5 kDa and for 
sTACI-short (16-20-W-68-135) at 8.1 kDa. Unexpectedly, sTACI-long dimer showed the 
highest peak/concentration in refractive index in SLS/SEC analysis indicating that sTACI-
long appeared mainly as a dimer (Figure 24 B). sTACI-short in comparison presented 
itself as a mixture of sTACI-short (1-20-W-68-154) and sTACI-short (16-20-W-68-135) 
(Figure 24 C). Both sTACI-short variants that were separated by SEC needed to be 
pooled to have enough protein for analysis. Thus, the higher oligomers that were seen in 
SEC analysis could not be detected and analyzed with SLS/SEC. We focused on the two 
main variants of sTACI-short (sTACI-short (1-20-W-68-154) and sTACI-short (16-20-W-
68-135)) as the amount of higher oligomers in sTACI-short observed by SEC made the 
detection of these oligomers with SLS/SEC rather unlikely. In summary, SLS/SEC led to 
more accurate estimations of the MW of the sTACI isoforms than SEC alone (Table 25). 
 
Table 25: Comparison of MW determination of sTACI isoforms with SLS/SEC system and 
SEC standard curve  
 
 
  
Construct Expected MW 
(kDa) 
SLS/SEC MW 
(kDa) 
SEC MW 
(kDa) 
sTACI-long dimer 34 30.2 58.3 
sTACI-long monomer 17.4 18.3 29.9 
sTACI-short 
(1-20-W-68-154)  
12.2 12.5 19.9 
sTACI-short  
(16-20-W-68-135) 
7 8.1 9.2 
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4.1.7. STABILITY OF sTACI-LONG DIMER AND MONOMER 
 
In an equilibrium, constructs are in a stable system. That means that the proportion 
of one element to the other element in the system is constant. If you remove one part of 
the system the equlibrium reinstates after some time. We tested if the dimer and monomer 
of sTACI-long form such a constant equilibrium by a provocation assay (Figure 25). 
During the incubation period, a development of an equilibrium state was not observed. 
The dimer (Figure 25 A) and monomer (Figure 25 B) of sTACI-long were stable. After 72 
h a small degradation-like band was observed in the sTACI-long monomer (Figure 25 B). 
 
 
Figure 25: Stability test of sTACI-long dimer and monomer 
The dimer and monomer of sTACI-long that were separated by SEC were tested in a provocation 
assay and analyzed by Coomassie staining. Above each band stands the timepoint at which the 
protein was taken during the experiment. sTACI-long dimer/monomer mix (A) and monomer (B) 
were incubated at 37 °C for 72 h.  
 
 
4.1.8. SUMMARY OF PROTEIN CHARACTERIZATION 
 
This part of the thesis showed that sTACI-long and sTACI-short were both 
produced recombinantly in HEK293.EBNA cells. First, we investigated both sTACI 
isoforms for N-linked glycosylation before mass spectrometry analysis. Neither of our 
sTACI proteins were N-linked glycosylated. Next, the identity of the recombinant TACI 
isoforms was confirmed by mass spectrometry and N-terminal sequencing. We observed 
closely located double bands for sTACI-long and sTACI-short in Western blot and 
Coomassie stained SDS-PAGE and a 5 kDa smaller band for sTACI-short. We were able 
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to characterize all bands by mass spectrometry and N-terminal sequencing. sTACI-short 
was revealed to be a mixture of sTACI-short (1-20-W-68-154) and sTACI-short (16-20-W-
68-135). We were able to determine changes within the N-terminal sequence for the 
observed closely located double bands of both sTACI-short and sTACI-long. Two out of 
three sequences of the N-terminal variations are predicted to be the result of intracellular 
Furin cleavage. The additional sequence of sTACI-short could not be attributed to a 
protease yet. Next, we analyzed both isoforms for oligomerization. We found that sTACI-
long presented itself mainly as a dimer as shown by Coomassie stained SDS-PAGE, 
Western blot, SEC and SLS/SEC. We also tested if the dimer and monomer of sTACI-
long were in a constant equilibrium. We found that both the dimer and the monomer were 
in a stable state without any equilibrium. The dimer was not influenced by heat-
denaturation or SDS-PAGE, whereas DTT could break its higher molecular bonds. sTACI-
short exhibited small amounts of oligomers in SEC. The existence of these oligomers 
could be verified by the analysis of their MW by SEC standard curve, hTACI ELISA, and 
with Coomassie stained SDS-PAGE of the concentrated oligomers. 
 
4.2. FUNCTIONAL ANALYSIS  
4.2.1. EVALUATION OF THE AFFINITY BY BINDING ELISA 
 
We used an ELISA based method to assess the binding affinity of sTACI-long and 
sTACI-short to their ligands BAFF and APRIL, similar to several previously described 
assays for affinity determination (136, 160-162). To compare the affinity of our different 
TACI variants we calculated a dissociation constant (Kd). The Kd represents the value of 
concentration at which the (binding-)reaction is in an equilibrium, that means half of the 
proteins are bound and the other half is free. Generally, a small Kd indicates a high affinity 
of a protein to its ligand. Figure 14 shows an illustration of the different constructs that 
were evaluated by this method. sTACI-long and sTACI-short appeared in different variants 
based on N-terminal truncation, presumably mediated by Furin-convertase (Figure 20). 
These truncations are N-terminal of the CRD2 and are not predicted to have a major 
impact on decoy function and ligand binding. The resulting difference in size between 
  
64 
 
these different variants is too small to separate them by SEC and analyze them 
separately. Thus, sTACI-long and sTACI-short were tested including these variants.  
First, we compared sTACI-long and sTACI-short with each other and tested 
different ligands (Figure 26 A+B). We found that sTACI-long and sTACI-short bound to 
BAFF with similar affinity (Figure 26 C). The affinity of both isoforms to APRIL was tested 
with mega- (mouse) (Figure 26 B) and human-APRIL (data not shown).  
We found that sTACI-short and sTACI-long exhibited high affinities for APRIL, although 
sTACI-long displayed a significantly higher affinity for mega-APRIL in comparison to 
sTACI-short (Figure 26 D). Human-APRIL led to similar results (data not shown) 
concerning affinity differences between sTACI-long and sTACI-short, but showed less 
overall affinity to both TACI isoforms. Human-APRIL showed additionally high background 
binding in HEK293T cells without transfected TACI in flow cytometry (data not shown). 
Thus, we chose mega-APRIL for our binding studies.  
We compared further CRD1-Fc, CRD2-Fc, CRD1+CRD2-Fc and CRD1+CRD2-Fc-
a (Figure 26 A+B). The exact sequences of all compared constructs are depicted in 
Figure 14. sTACI-short (W-68-154), was additionally created to analyze whether the first 
20 amino acids of the sequence affect binding to BAFF and mega-APRIL. All constructs 
including sTACI-short bound to BAFF significantly better than CRD1-Fc (Figure 26 C). 
When we looked at mega-APRIL affinity we found that sTACI-short, sTACI-short (W-68-
154) and CRD1-Fc bound significantly worse to mega-APRIL when compared to the other 
constructs (Figure 26 D). The difference between sTACI-short and CRD1-Fc in APRIL 
affinity was not significant. Thus, CRD1-Fc bound both BAFF and APRIL only weakly. 
sTACI-short (W-68-154) bound too weekly to mega-APRIL to calculate any Kd.  
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Figure 26 : Binding of various TACI constructs to BAFF and APRIL measured by ELISA 
(A+B) V-bottom plates were coated with anti-FLAG antibodies (5 µg/ml). FLAG-tagged BAFF- or 
mega-APRIL were added (100 ng/ml) and a dilution series of the different constructs were applied. 
On the x-axis stands the concentration of the used dilution series and on the y-axis the OD450 
normalized against the background binding of the used ligand (normalized against BAFF (A) or 
mega-APRIL (B)). (C+D) Scatter blot of normal one way ANOVA (*P<0.05, **P<0.005, 
***P<0.0005, ****P<0.00005); Combined data of three (sTACI-short (W-68-154), CRD1+CRD2-Fc 
and CRD1-Fc), five (sTACI-long and sTACI-short) or six (atacicept and CRD2-Fc) independent 
experiments (mean +/- SEM).  
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Next, we analyzed the different fractions of sTACI-long and sTACI-short that were 
separated by SEC (Figure 27). We did this comparison mainly because of the two 
following reasons. First, we wanted to see if dimerization led to an increased affinity in our 
proteins. Second, we wanted to rule out that sTACI-short (16-20-W-68-154) lost its 
functionality within the BAFF/APRIL system. Both effects could contribute and partly 
explain the decreased affinity of sTACI-short to mega-APRIL.  
Coomassie stained SDS-PAGE was performed immediately prior to application of 
the proteins to the plates. We wanted verify that the different pooled fractions remained in 
the same state they were originally separated and stored at. It was found that the 
separated fractions remained in the same state that they were frozen in (Figure 27 A). 
The dimer fraction was comprised of a mixture of monomer and dimer. The amount of 
dimer was enriched in that fraction. All other fractions were separated completely.  
The comparison of the dimer and monomer of sTACI-long revealed significant 
differences in their affinities for BAFF and mega-APRIL (Figure 27 B+C). The dimer of 
sTACI-long bound to BAFF and mega-APRIL significantly better than the monomer 
(Figure 27 F+G). When we compared sTACI-short (1-20-W-68-154) and sTACI-short (16-
10-W-68-135) (Figure 27 D+E), we detected no difference in their binding properties for 
BAFF (Figure 27 H). When we analyzed the affinity for mega-APRIL, we found that the 
full-length sTACI-short (1-20-W-68-154) was able to bind to mega-APRIL significantly 
better than sTACI-short (16-20-W-68-135) (Figure 27 I).  
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Figure 27: Binding of SEC-separated fractions of sTACI-long and sTACI-short to BAFF 
and APRIL measured by ELISA 
(A) Coomassie stained SDS-PAGE of different sTACI fractions. (B-E) V-bottom plates were coated 
with anti-FLAG antibodies (5 µg/ml). FLAG-tagged BAFF- or mega-APRIL were added (100 ng/ml) 
and a dilution series of the different fractions was applied. On the x-axis stands the concentration 
of the dilution series and on the y-axis the OD450 normalized against the background binding of 
the used ligand (normalized against BAFF (B, D) or mega-APRIL (C, E)). (F-I) Scatter plot of 
unpaired two-tailed t-test with Welch’s correction for B-D (ns: not significant; *P<0.05, **P<0.005, 
***P<0.0005) Combined data of three independent experiments (mean +/- SEM).  
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Table 26 shows the summary of mean Kd values from each construct for BAFF 
and mega-APRIL.  
 
Table 26: Binding affinity of BAFF and APRIL to TACI-constructs.* 
TACI construct BAFF  
Kd (pM) 
mega-APRIL  
Kd (pM) 
sTACI-long 100 292 
sTACI-long dimer 72 127 
sTACI-long monomer 106 447 
sTACI-short 270 5960 
sTACI-short  
(1-20-W-68-154) 
187 4434 
sTACI-short 
(16-20-W-68-135) 
301 7741 
sTACI-short 
(W-68-154) 
1065 n.a. 
CRD1+CRD2-Fc-a 54 93 
CRD1+CRD2-Fc 139 346 
CRD2-Fc 30 77 
CRD1-Fc 54160 14470 
*N.a. means that the interaction that was measured was too low to calculate the Kd. Means were 
calculated from 3-6 experiments. Both isoforms of sTACI were analyzed as mixtures. sTACI-long 
preparations contained a dimeric and a monomeric form, while sTACI-short was a mixture of the 
monomeric sTACI-short (1-20-W-68-154) and sTACI-short (16-20-W-68-135) and to a small 
extent higher oligomers of sTACI-short. The different fractions of the sTACI-long and sTACI-short 
preparations were separated by SEC (Figure 21 + Figure 27) and analyzed independently.  
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4.2.2. EVALUATION OF DECOY FUNCTION BY LUCIFERASE ASSAY 
(NFκB ASSAY) 
 
A luciferase based assay (NFκB assay) was used as a second read out system, 
complementary to the Binding ELISA. The NFκB assay is a reporter cell assay that can 
be used to test the decoy function of soluble receptors. The IC50 was calculated to 
indicate the potency of soluble receptors in inhibiting NFκB activation. The IC50 means 
the concentration of a soluble receptor that is needed for the NFκB activation to be 
decreased for 50%.  
First, we compared sTACI-long to sTACI-short for their decoy function (Figure 28). 
sTACI-long and sTACI-short displayed a similar decoy function for BAFF (Figure 28 A+F). 
Both receptors were able to act as decoy receptor for BAFF at high concentrations. In 
contrast, only sTACI-long was able to capture mega-APRIL (Figure 28 B+E) and human-
APRIL (Figure 28 C) at high concentrations and thus prevent NFκB activation (Figure 28 
B+C). sTACI-short was not able to act as decoy receptor for mega- or human-APRIL and 
thus showed no influence on NFκB activation. The monomer and dimer of sTACI-long 
were tested for their decoy function after a significant difference was detected in their 
ability to bind mega-APRIL by binding ELISA (Figure 28 D,E,G,H). In concordance with 
the findings of our binding ELISA, we were able to detect significant differences for the 
decoy function between the dimer and monomer of sTACI-long for BAFF and APRIL 
(Figure 28 G+H). Table 27 shows the summary of mean IC50 values from each measured 
construct for BAFF and mega-APRIL.  
 
Table 27: Decoy activity of sTACI-long, sTACI-long dimer, sTACI-long monomer and 
sTACI-short for BAFF and APRIL*  
TACI BAFF 
IC50 (nM) 
mega-APRIL 
IC50 (nM) 
Human-APRIL 
IC50 (nM) 
sTACI-long 1.791 1.982 4.443 
sTACI-long dimer 0.438 1.762 - 
sTACI-long 
monomer 
1.176 6.807 - 
sTACI-short 1.679 n.a. n.a. 
*N.a. means that the interaction that was measured was too low to calculate the IC50 and the 
straight line (-) means that the receptors were not tested with that ligand. Means were calculated 
from 3-6 experiments. 
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Figure 28: Decoy activity of TACI constructs for BAFF and APRIL measured by NFκB 
assay NFκB assay 
(A-E) HEK293T cells were transfected with BCMA (2.5 ng), Renilla (40 ng) and Firefly (40 ng). 
FLAG-tagged BAFF, mega- or human-APRIL (100 ng/ml) were added together with a dilutions 
series of sTACI-long or sTACI-short. The concentration of the sTACI-isoforms is represented on 
the x-axis, the NFκB fold induction on the y axis (F-H) Scatter blot of unpaired two-tailed t-test with 
Welch’s correction for A, D, and E (ns: not significant; *P<0.05). Combined data of six (A and B) 
or three (C,D,E) independent experiments (mean +/- SEM).  
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4.2.3. SUMMARY OF FUNCTIONAL TESTS 
 
In the second part of this thesis, we analyzed sTACI-long and sTACI-short for their 
ligand-binding and functionality with two different read-out systems, binding ELISA and 
NFκB reporter assay. We found that both isoforms of TACI showed a similar affinity for 
BAFF, while sTACI-long bound to APRIL with significantly higher affinity than sTACI-short. 
In a second read-out system, an NFκB reporter assay, similar results were obtained. Using 
SEC separated fractions, we found that the dimer of sTACI-long showed significantly 
higher affinity to BAFF and APRIL than the monomer. Three constructs of sTACI-short 
that differed in the sequence in the N-terminal side outside of CRD2 were available and 
tested for ligand binding. sTACI-short (1-20-W-68-154), sTACI-short (16-20-W-68-135), 
and sTACI-short (W-68-154) displayed similar binding affinities for BAFF, while sTACI-
short (1-20-W-68-154) bound significantly better to APRIL than sTACI-short (16-20-W-68-
135) and sTACI-short (W-68-154). sTACI-short (16-20-W-68-135) lacks 19 amino acids 
at the C-terminus outside of the CRD2 which are present in the other two versions of 
sTACI-short. This could contribute to the reduced binding affinity to APRIL. The abolished 
APRIL binding of sTACI-short (W-68-154) indicates, however, that the N-terminal part is 
crucial for binding to APRIL. Thus, these amino acids N-terminal outside of CRD2 have 
little effect on BAFF-binding, but seem to contribute to the (weak) APRIL binding of sTACI-
short. The two isoforms of sTACI were compared to TACI-Fc constructs, comprising 
CRD1 and CRD2 individually or together and to an atacicept analog (CRD1+CRD2-Fc-a). 
We found that CRD1+CRD2-Fc, CRD2-Fc and CRD1+CRD2-Fc-a
 
exhibited similar high 
affinities for BAFF and APRIL, while CRD1-Fc showed little ligand binding. Surprisingly, 
CDR2-Fc appeared different from sTACI-short with respect to APRIL binding.  
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4.3. MEMBRANE-BOUND TACI ISOFORMS 
4.3.1. ASSESSMENT OF THE EXPRESSION, SHEDDING AND LIGAND 
INTERACTION OF TACI-LONG AND TACI-SHORT FROM HEK293T 
CELLS 
 
We tested transfected HEK293T cells for their expression, ligand binding and 
shedding of TACI-long and TACI-short. HEK293T cells were chosen because they do not 
express TACI endogenously. Flow cytometry was used to assess surface expression 
(membrane-bound TACI) and binding of ligands. ELISA was applied to test for shedding 
(sTACI).  
Both TACI-long and TACI-short were expressed and constitutively shed from 
transfected HEK293T cells. TACI-short was shed in significantly higher amount from the 
cell surface than TACI-long (Figure 29 A). In concordance, TACI-short expression was 
higher on HEK293T cells than TACI-long expression (Figure 29 B), when equal amount 
of plasmids were used for transfection. At the highest amount of transfected plasmid (100 
ng) TACI-short was expressed significantly higher than TACI-long.  
 
 
 
Figure 29: Expression and shedding of TACI-long and TACI-short by transfected 
HEK293T cells 
(A-D) HEK293T cells were transfected with increasing amounts of TACI-long or TACI-short. (A) 
The amount of shed TACI was determined by ELISA. (B) Surface expression was analyzed by 
flow-cytometry. The MFI was calculated by subtracting the signal from non-transfected cells from 
the signal of transfected cells. (Combined data of five independent experiments (mean +/- SEM), 
unpaired two-tailed t-test (*P<0.05). 
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The binding capacity of the membrane-bound TACI isoforms for BAFF and mega-
APRIL was analyzed with our cell based assay as well. HEK293T cells were transfected 
with different amount of TACI-long or TACI-short similar to the expression assay. In an 
additional step, FLAG®-tagged BAFF or mega-APRIL was added in a constant 
concentration and ligand binding was assessed by flow cytometry. We could replicate in 
concordance with our previous findings, that TACI-short is expressed significantly more 
on transfected HEK293T cells than TACI-long. We found that both membrane-bound 
isoforms can bind to BAFF and mega-APRIL. Both TACI isoforms bound to BAFF and 
APRIL similarly (Figure 30 A+B). In a different assay setup we tried constant amounts of 
transfected plasmid and varied the concentration of BAFF and mega-APRIL. Unspecific 
binding of mega-APRIL, when higher amount than 100 ng/ml were added, limited this 
approach. Human-APRIL could not be used at all for this assay as it displayed already in 
small amounts unspecific binding (data not shown).  
  
Figure 30: Analysis of membrane-bound TACI-long and TACI-short BAFF and APRIL 
interaction 
(A and B) HEK293T cells were transfected with increasing amounts of TACI-long or TACI-short. 
BAFF- (A) or mega-APRIL-FLAG (B) (100 ng/ml) were added. The binding of BAFF and mega-
APRIL was analyzed by flow-cytometry. The MFI was calculated by subtracting the isotype signal 
of non-transfected cells with BAFF or APRIL-FLAG from the signal of transfected cells. Combined 
data of three independent experiments (mean +/- SEM). 
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4.3.2. CO-IMMUNOPRECIPITATION OF TACI-LONG AND TACI-SHORT 
IN SOLUBLE AND MEMBRANE-BOUND FORM 
 
Co-IP was used to analyze for homo- or heterotypic interaction of both TACI 
isoforms in soluble and membrane-bound form in one single assay. Therefore, TACI-short 
was cloned with a N-terminal FLAG®-tag or HA-tag. No interaction between BCMA and 
TACI has been reported so far. BCMA with a FLAG®-tag was used for comparison.  
The efficiency of the IP was tested by anti-FLAG® ELISA (Figure 31). The FLAG®-
tag was used to immunoprecipitate proteins with anti-FLAG®-tagged beads. Each 
condition was tested for TACI and BCMA occurrence with pre and post IP samples by 
ELISA. Conditions with FLAG®-tagged proteins could be detected pre IP and post IP for 
both soluble (Figure 31 A) and membrane-bound proteins (Figure 31 B). Exclusively HA-
tagged conditions could not be detected after IP. The existence of TACI in solely HA-
tagged conditions pre IP was verified by hTACI ELISA (Figure 31 C+D). Therefore, the 
IP was able to specifically extract FLAG®-tagged proteins from our samples. 
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Figure 31: Test of efficiency of IP 
(A -D) HEK293T cells were transfected with the indicated plasmids. The supernatants (A,C) and 
cell-lysates (B,D) were harvested 48-72h after transfection. Small fractions of each condition were 
saved before FLAG®-IP. The pre- and post IP samples were then measured by anti-FLAG® ELISA 
(A and B) or hTACI ELISA (C and D) on ELISA plates. The proteins were either detected by an 
anti-TACI detection antibody or anti-BCMA detection antibody (for BCMA-FLAG in anti-FLAG® 
ELISA). The green arrow indicates pre IP and HA-tag only conditions in hTACI ELISA. Combined 
data of three independent experiments (mean +/- SEM).  
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In principle, HA-tagged proteins could only be detected post IP if these proteins 
formed an interaction with FLAG®-tagged proteins. Thus, the HA-tagged proteins were 
not lost during IP. The anti-HA ELISA was used to distinguish if our proteins formed such 
an interaction with each other in a homotypic or heterotypic way. We tested this for both 
soluble (supernatant) (Figure 32 A) and membrane-bound (cell-lysate) proteins (Figure 
32 B). No difference could be detected between soluble and membrane-bound conditions. 
We found that TACI-long interacted homotypically with itself, as previously described (93). 
Similarly, TACI-short showed the same homotypic interaction and both TACI-short and 
TACI-long interacted heterotypically with each other. No interaction of BCMA with either 
of the TACI isoforms could be detected. 
 
 
 
Figure 32: Analysis of homo- and heterotypic interaction of TACI isoforms in soluble and 
membrane-bound form 
(A and B) HEK293T cells were co-transfected with plasmids that contained either a HA- or FLAG®-
tag. The different conditions are indicated in the legend below the graph. The supernatants and 
cell-lysates were harvested 48-72 h after transfection. Small fractions of each condition were 
saved before FLAG®-IP. The pre- and post IP samples were then measured by anti-HA ELISA. 
The proteins were detected by an anti-TACI detection antibody. Combined data of three 
independent experiments (mean +/- SEM).  
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4.3.3. SUMMARY OF THE ANALYSIS OF MEMBRANE-BOUND 
ISOFORMS OF TACI  
 
In this last part of this thesis we found that both TACI-long and TACI-short were 
expressed on and spontaneously shed into the cell culture medium from the membrane 
of transiently transfected HEK293T cells. TACI-short levels were significantly higher on 
the cell membrane and in the cell culture medium. Both membrane-bound isoforms of 
TACI bound to BAFF and mega-APRIL similarly. The homotypic interaction of the soluble 
and membrane-bound TACI isoforms was further evaluated by Co-IP. We have shown 
that both TACI-long and TACI-short form homotypic interactions and that TACI-short and 
TACI-long exhibited a heterotypic interaction with each other in soluble and membrane-
bound form. No interaction of TACI isoforms and BCMA was detected. 
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5. DISCUSSION 
5.1.  BASIC CHARACTERIZATION OF sTACI-LONG AND 
sTACI-SHORT  
 
In this project, we aimed to investigate the molecular characteristics and functions 
of two different TACI isoforms (sTACI-long and sTACI-short) by generating proteins that 
have the identical sequence with the endogenously shed TACI that our lab had recently 
identified (93). Our previous studies found so far that (i) TACI gets shed by the protease 
ADAM10 from activated B-cells, (ii) TACI interacts homotypic in soluble and membrane-
bound form and (iii) sTACI exits in vivo in B-cell pathologies (93, 163). sTACI-long and 
sTACI-short differ from each other on the extracellular domain. sTACI-long expresses 
both CRDs (CRD1 and CRD2), while TACI-short only the CRD2 as a consequence of 
alternative splicing (Figure 6) (140). Both isoforms of TACI were analyzed in membrane-
bound form by a previous study that reported that TACI-short is more potent inducing 
plasma cell differentiation (146).  
 
5.1.1. PURITY  
 
We produced the two isoforms of sTACI recombinantly, secreted from 
HEK293.EBNA cells (153). Combined analysis of Coomassie stained SDS-PAGE, 
Western blot, mass-spectrometry and N-terminal sequencing yielded only TACI indicating 
the purity of the recombinantly produced proteins. The purity of our proteins was the result 
of on the one hand usage of serum-free medium during expression and on the other hand 
purifying them with an affinity based method.  
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5.1.2. DIFFERENT VARIANTS OF sTACI-LONG AND sTACI-SHORT 
OUTSIDE OF THE CYSTEINE RICH DOMAINS 
 
We noticed that both of our TACI isoforms did not appear as a single band in 
Coomassie stained SDS-PAGE and Western blot. Both isoforms were rather comprised 
of double bands, while sTACI-short showed an additional 5 kDa smaller variant. We 
analyzed all variants by mass spectrometry and N-terminal sequencing. The 5 kDa smaller 
variant of sTACI-short was revealed to be missing parts on both the C- and N-terminal 
side. Thus, our sTACI-short preparations were a mixture of full-length sTACI-short (1-20-
W-68-154) and sTACI-short (16-20-W-68-135). N-terminal sequencing revealed further 
heterogeneity within the sequence of sTACI-long and sTACI-short on the N-terminal side, 
which we could largely attribute to Furin cleavage. Furin is a protease primarily located at 
the Golgi apparatus (159). The cleavage points that we observed for our sTACI-long and 
sTACI-short are depicted in Figure 20 together with the canonical sequences of the Furin 
protease. Cleavage by Furin often leads to activation of proteins like for example observed 
for shiga toxin, Influenza virus hemagglutinin, and the hepcidin regulator hemojuvelin 
(159, 164-166). We found an additional variant of the N-terminus for sTACI-short that we 
could not attribute to a protease yet.  
 
5.1.3. OLIGOMERIZATION OF sTACI ISOFORMS 
 
Coomassie stained SDS-PAGE and Western blot revealed possible oligomers of 
our sTACI isoforms. We found that our recombinantly produced sTACI-long built mainly 
dimers and to a smaller extent monomers, whereas sTACI-short appeared mainly as 
monomer and in small amounts as higher oligomers. SEC and SLS/SEC analysis 
confirmed our previous observations that sTACI-short appeared mainly as a mixture of 
the monomers sTACI-short (1-20-W-68-154) and sTACI-short (16-20-W-68-135).  
Thus, both isoforms of sTACI are able to form oligomers. It was previously 
described that the CRD1 is needed for oligomerization of surface TACI (145). 
Nevertheless, our sTACI-short which lacks the CRD1 built oligomers indicating that 
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oligomerization seems to not solely depend on the CRD1. The differing ways of 
oligomerization of both sTACI isoforms could, however, be the result of different 
interactions. Earlier studies support the role of the CRD1 in dimerization of TACI-long 
(145). In general, additional CRDs are reported to bring extra abilities to other TNF 
receptors. The additional CRDs stabilized the receptors and increased the affinity and 
specificity of the receptors to their ligands (140, 167-170). Moreover, another study 
proposed that the CRD1 of TACI was an evolutionary relict by reporting that it cannot 
contribute to ligand/receptor interactions with BAFF and APRIL (140). Taken together, the 
main role and function for the CRD1 could be the dimerization and stabilization of TACI-
long, while the cause of oligomerization in sTACI-short remains unknown. 
Concerning the observed dimerization of sTACI-long, we assessed its stability with 
several different conditions. We found that heat denaturation did not disrupt the dimers 
and that there was no state of equilibrium between the dimer and monomer, at 
physiological conditions. This observation suggested that the dimer was formed by a 
highly stable bond. Only DTT, which is a reducing agent, was able to break the bond, 
further supporting our hypothesis.  
This highly stable covalent interaction could be caused by disulfide bonds (171). 
Disulfide bonds are important posttranslational modifications that contribute to proper 
folding, stabilization and functionality of proteins (172). The redox reaction that generates 
these bonds takes part in the ER (173). Cleavage of disulfide bonds can exert regulatory 
effects (172). This effect was shown for several receptors like the scavenger receptor 
class B, type 1 (SR-B1), vasopressin V2 receptor (V2-R), and Thyrotropin-releasing 
Hormone Receptor (TRH-R) (174-177) . Several disulfide bonds are predicted for the 
CRDs of TACI on the extracellular domain (Figure 33) (140).  
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Figure 33: Sequence alignment of the CRD1 (TACI_d1), CRD2 (TACI_d2), BAFF-R (BR3) 
and BCMA 
CRD1, CRD2 and BCMA share the identical arrangement of their cysteine residues. The proposed 
interaction between these residues is indicated by the connecting brackets above the sequence. 
The residues are all connected in inner-molecular disulfide bonds. Figure taken from (140). 
 
 
Disulfide bonds could either directly be involved in generating a disulfide-linked 
dimer, or as intramolecular bonds that induce proper formation and folding for protein 
interaction. Interestingly, the mutation C104R within the extracellular domain of TACI - a 
mutation associated with the diseases common variable immune deficiency (CVID) and 
IgA deficiency (IgAD) (120-122, 127, 145, 178, 179) - is located at the cysteine at position 
104 which is predicted to form an intramolecular disulfide bond with the cysteine at 
position 93 (140). A mutation at that position abolishes the proposed disulfide bond which 
could explain the changed properties of C104R mutated TACI, although no effect could 
be observed at receptor preassociation (145). The mutation was shown to annihilate 
ligand binding and intracellular signaling (120, 121, 178) and is discussed to increase 
susceptibility to disease outbreak (127).  
Whether disulfide bonds are the cause of oligomerizations of TACI could not be 
shown yet. Previous studies detected oligomerization of soluble TACI-long by Co-IP (93) 
and of membrane-bound TACI by crosslinked cell surface molecules in murine B-cells 
(145), Förster resonance energy transfer (FRET) analysis independent of a ligand (145) 
and Co-IP (93, 145). Sequential nondenaturing IP revealed that TACI assembled at least 
as trimer in the ER (145). In that study DTT was able to break higher oligomers of cross-
linked TACI in cell lysates, but without any explanation. In other TNF receptors 
extracellular disulfide bonds were shown to attribute to native dimerization such as for the 
death receptor 5 (180) and CD40 (181-183). Both receptors exhibited extracellular 
disulfide-linked dimers. The addition of a reducing agent broke both dimers (180, 181). 
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The dimerization of CD40 is controversially discussed, since another study attributes 
dimerization to the CRD1 of CD40 (184). 
Another N-terminal variant of sTACI-short that was cloned, namely sTACI-short-
(W-68-154) showed the tendency to build several high grade oligomers already quite 
prominent in Coomassie stained SDS-PAGE. In contrast to our recombinantly produced 
sTACI-short, we did not find an additional degraded sTACI (16-20-W-68-135)-like variant 
in our sTACI-short (W-68-154) preparation. Therefore, the terminal stalk right before the 
transmembrane region (amino acids 135-154) of sTACI-short could contribute to the low 
level of oligomers formed by sTACI-short. An additional assay was performed with sTACI-
short (W-68-154) to further assess its oligomerization. It was tested, whether the simple 
addition of EDTA, which is potent at forming chelates with divalent ions, abrogates 
oligomerization by capturing Nickel ions. Therefore, the formation of a chelate between 
eluted Nickel ions from HisTrap columns and the His6-tag of sTACI-short (W-68-154) 
would be prevented. This phenomenon was suggested previously to explain the formation 
of the BAFF60mer, although it was found that the BAFF60mer was not the consequence 
of such an interaction (84, 85). Accordingly to the BAFF60mer, addition of EDTA had no 
effect on oligomerization of sTACI-short (W-68-154). Following studies could further 
evaluate the disulfide bonds of TACI. An urea gel could be run to determine whether our 
oligomers are linked by intermolecular disulfide bonds. In principle, urea denaturizes 
proteins by destruction of their tertiary structure (177, 185-187).  
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5.1.4. GLYCOLSYLATION OF TACI ISOFORMS 
 
Last, we investigated the glycosylation of our proteins. Glycosylation was shown to 
have effects on ligand/receptor interactions and membrane assembly of receptors in 
previous studies (188, 189). N-linked glycosylation was predicted at amino acid 128 (N) 
for TACI by Uniprot. We found that both of our recombinantly produced isoforms were 
missing the predicted N-linked glycosylation as proven by PNGase F (Figure 20).  
N-linked glycosylation was shown to have an important regulatory effect on BCMA 
(190). BCMA expresses a single N-linked glycosylation site on the extracellular domain at 
asparagine 42. In BCMA small changes and different parts of the glycosylation pattern 
affected the function by improving ligand binding and causing either cell surface retention 
or removal of BCMA (190).  
It remains to be clarified whether the sTACI shed from B-cells also lacks N-linked 
glycosylation, since glycosylation could be different in HEK293T- and B-cells. Future 
studies should investigate the glycosylation of B-cell derived TACI and sTACI. Therefore, 
supernatants of the Raji cell line (191-193) – a lymphoblast cell line that expresses TACI- 
could be concentrated, followed by separation of sTACI-long and sTACI-short by SEC 
and analysis for glycosylation by PNGase F. 
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5.2.  LIGAND BINDING AND DECOY FUNCTION OF sTACI-
LONG AND sTACI-SHORT    
 
To analyze interactions of TACI-variants and their ligands, we used two different 
read out systems, namely ELISA and NFκB assay. In general, ELISA or surface plasmon 
resonance (SPR) based methods can be used to determine affinity and calculate Kd 
values (136, 160, 161, 194, 195). Both methods detect different reactions and 
consequently differ in exact values, but the general conclusions are mostly uniform and 
equivalent between both methods (196). In our binding ELISA we immobilized FLAG®-
tagged BAFF and APRIL to pre-coated anti-FLAG® antibodies on the plate and added a 
dilutions series of sTACI in molar concentration which we then detected by colorimetry. 
Another previously described ELISA based method which was used to evaluate the 
binding affinity of BCMA-Fc and TACI-Fc (basically TACI-long) to BAFF and APRIL 
showed that BCMA-Fc and TACI-Fc exhibit similar affinities to BAFF and APRIL (136). In 
that study BCMA and TACI were used as Fc fused homodimers. BCMA-Fc and TACI-Fc 
were immobilized to plates and BAFF or APRIL were added in a dilution series (136). For 
our second read out system - the NFκB assay- we used an inhibition based method and 
determined the IC50 essentially as published (93). We transfected HEK293T cells with 
BCMA and added a mixture of BAFF or APRIL with a dilution series of TACI and checked 
for NFκB activation.  
We found that sTACI-long and sTACI-short exhibited similar affinity and decoy 
function for BAFF. In contrast, sTACI-long bound with significantly higher affinity to APRIL 
than sTACI-short. In harmony with this observation, only sTACI-long was able to act as a 
decoy receptor for APRIL. A previous study from our lab showed that sTACI can bind to 
BAFF and APRIL and that it acts as a decoy receptor for both ligands (93), which is 
confirmed in this study. That study did not compare the different isoforms of TACI, it only 
analyzed the full-length isoform which represents sTACI-long.  
Another study analyzing the contributions of CRD1 and CRD2 of TACI to binding 
of BAFF and APRIL concluded that only CRD2 is needed for high affinity-binding to both 
ligands (140). CRD1 alone bound only weakly; when CRD1+CRD2 (basically sTACI-long) 
was compared to CRD2 only (basically sTACI-short), the CRD1 did not contribute 
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substantially to ligand binding (140). While many of these results are similar to the ones 
obtained here with the sTACI variants, one difference appeared. In that study (140), CRD2 
showed a strong APRIL binding, while in our study sTACI-short showed only a weak 
APRIL binding.  
Possible reasons for the different results could be (a) different methods to 
determine the affinity, (b) sequence differences beyond the CRDs, (c) differences in the 
used protein expression systems, (d) differences in state of oligomerization, (e) and 
differences in the applied variant of APRIL. 
(a) That study used different methods to determine the affinity (140). First, an 
inhibition assay was used which measured binding kinetics by SPR (194, 195). In that 
assay BCMA-Fc was coupled to a chip and different amounts of TACI were added 
together with constant amounts of BAFF and APRIL (140). The aim of that assay was to 
calculate the ability of TACI to inhibit the binding of BAFF and APRIL to BCMA-Fc (IC50). 
Second, a competitive ELISA assay was used as an additional read out system. The 
competitive ELISA assay was designed as an inhibition assay as well (IC50). BAFF and 
APRIL were coupled to plates and a mixture of each TACI construct with a dilution series 
of soluble BAFF and APRIL was added. The concentration of the receptors was not used 
in molarity in contrast to our study if the indicated protocol was followed (140, 141). As 
previously described, all methods for the determination of affinity mostly lead to the same 
conclusions (196). Therefore, other effects are most likely to cause the differences we 
observed between our sTACI isoforms and that study.  
(b) The constructs of that study were designed to start directly at the CRDs of TACI 
and not as full-length proteins like ours (Figure 34). Indeed, we observed that the N-
terminal part of sTACI-short outside of the CRD2 have an effect on APRIL binding as 
described below. Our observation that sTACI-short (W-68-154) showed almost no APRIL 
interaction shows that the N-terminus outside of CRD2 is not the reason for the discrepant 
results. Nevertheless, our sTACI-short extended to amino acid 154 or 135, while the 
CRD2 used in that study stops at amino acid 109. The C-terminal part outside of CRD2 
would not be expected to contribute to APRIL binding, although this has not been analyzed 
specifically.  
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Figure 34: Sequence of the TACI constructs from Hymowitz et al (Figure taken from (140)) 
 
 (c) The proteins of that study (140) were produced in E. coli and insect cells, while 
we produced in eukaryotic HEK.EBNA cells. In detail, the CRD2-version was produced in 
E. coli. In general, recombinant protein production in E. coli gives high yields of protein 
and is fast, but it can lead to misfolded, aggregated, and degraded proteins that lack the 
posttranslational modifications of native human proteins (197, 198). Regardless, the 
CRD2 construct of that study (140) was shown to be fully functional concerning BAFF and 
APRIL binding. The constructs that were comprised of the CRD1 and CRD1+CRD2 were 
produced differently by using baculovirus expression system with Hi5 cells. This method 
enables the generation of active proteins that highly depend on posttranslational 
modifications, proper folding and disulfide bonds (199). Expression in insect cells was 
reported to yield functional CRD1 and CRD1+CRD2 constructs likewise to the E. coli 
expressed variant of CRD2 (140). Our eukaryotic expressed isoforms of sTACI were fully 
functional within the BAFF/APRIL system. Therefore, the choice of different expression 
systems is most likely not the reason for the different results. 
(d) We noted a difference in oligomerization between the sTACI isoforms in our 
preparations. sTACI-long was mainly formed as a dimer, whereas sTACI-short was 
primarily in monomeric form. In that study (140), it was not reported whether the applied 
CRD domains were monomeric or oligomeric. To further assess the effect of 
oligomerization and to address the seemingly discrepant results, we analyzed TACI-Fc 
constructs, which are dimers due to the Fc-tag. Using these constructs, we basically 
obtained similar results as in that study (140). Specifically, we found that CRD1+CRD2-
Fc, CRD2-Fc and an atacicept analog (CRD1+CRD2-Fc-a) showed no difference in their 
capability to bind to BAFF and APRIL, whereas CRD1-Fc exhibited little BAFF and APRIL 
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interaction. Thus, a different state of oligomerization of sTACI-short versus CRD2-Fc 
could be an explanation for the different observations in this study and in (140).  
(e) This and the previous study (140) observed consistently that murine APRIL 
bound human TACI better than human APRIL. In that study trimeric murine APRIL (76) 
was used, while we used APRIL as an ARCP fused hexamer. It is unclear whether this 
contributes to the different results.  
Hence, the most plausible explanation for our observed differences of affinity is the 
state of oligomerization of sTACI-short versus CRD2-Fc. The importance of dimerization 
for ligand binding has been observed in several previous studies (94, 200-203). For 
example, it was shown that different binding properties exist between sBCMA and BCMA-
Fc (94). sBCMA is like sTACI shed from the cell surface and exists as a soluble receptor 
(94). sBCMA was produced with the same expression assay as our sTACI isoforms (94, 
153). It was demonstrated that sBCMA was able to bind APRIL, while BCMA-Fc was able 
to bind BAFF and APRIL (94). This finding is in concordance with another study which 
observed similar findings when they compared BCMA-Fc which is a homodimer with a 
monomeric version of BCMA (203). The dimerization increased the binding affinity of 
BCMA (203).  
To further validate our theory, we compared the dimer to the monomer of sTACI-
long. We were able to separate the dimer from the monomer by SEC. We could detect a 
significant improvement of binding to BAFF and APRIL for the dimer, which we could also 
replicate by NFκB assay. We could confirm that oligomerization improves ligand/receptor 
interaction. 
We noted that our sTACI-preparations contained variants that differ in the length of 
the stretches outside of the CRDs. This allowed us to analyze the contributions of these 
stretches to ligand binding. Specifically, our sTACI-short preparation contained the full-
length sTACI-short (1-20-W-68-154) and sTACI-short (16-20-W-68-135) which we 
separated by SEC. Additionally, we cloned sTACI-short (W-68-154) as another N-terminal 
variant. We compared the three N-terminal variants for their binding properties to analyze 
a possible contribution of the N-terminal amino acids to ligand binding. We found that all 
N-terminal variants showed no difference in binding to BAFF. In contrast, sTACI-short (1-
20-W-68-154) bound with significantly higher affinity to APRIL than sTACI-short (16-20-
W-68-135) and sTACI-short (W-58-154). sTACI-short (16-20-W-68-135) lacks 19 amino 
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acids at the C-terminus outside of the CRD2 which are present in the other two versions 
of sTACI-short. This could contribute to the reduced binding affinity to APRIL. The 
abolished APRIL binding of sTACI-short (W-68-154) indicates, however, that the N-
terminal part is crucial for binding to APRIL. Hence, these amino acids N-terminal outside 
of CRD2 have little effect on BAFF-binding, but seem to contribute to the (weak) APRIL 
binding of sTACI-short.  
The BAFF/APRIL system is very diverse. Further analysis of our proteins with all 
different variations of ligands like the BAFF60mer (83) or the heterotrimers of BAFF and 
APRIL (74, 88, 89) could improve the understanding of this complex system.  
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5.3. EXPRESSION, SHEDDING, LIGAND BINDING AND 
OLIGOMERIZATION OF MEMBRANE-BOUND TACI-LONG 
AND TACI-SHORT 
5.3.1. EXPRESSION, SHEDDING AND LIGAND BINDING 
We found that TACI-short was expressed and also constitutively shed in higher 
amount from transiently transfected HEK293T cells than TACI-long. Both TACI-long and 
TACI-short could bind to BAFF and APRIL.  
TACI had already been tested by cell based assay for its binding ability to BAFF 
and APRIL after identifying TACI as a possible receptor for BAFF (137, 146, 204). It was 
shown that TACI could bind to BAFF and APRIL in a similar assay set up as ours and that 
binding of the ligands lead to NFκB activation (137). Another study compared membrane-
bound TACI-long and TACI-short (146). That study found that (i) both isoforms are equally 
expressed when transfected on a murine B-cell line, (ii) both isoforms can bind to BAFF 
and APRIL and (iii) the shorter isoform seems to be more potent at inducing plasma cell 
differentiation independent of a ligand (146). 
Concerning membrane-bound studies, several different possibilities should be 
taken under consideration for future studies. Higher expression of TACI-short in 
comparison to TACI-long could lead to higher amount of BAFF and APRIL bound to TACI-
short transfected cells. In general, cell surface oligomerization is known to be important 
for interaction of ligands with transmembrane receptors (205, 206), which most likely 
correlates to membrane-expression. First, the difference of expression of our isoforms 
could be compensated by co-transfecting the constructs with an EGFP tracer for 
expression (151, 207). The EGFP tracer would be used to indicate the general transfection 
and expression efficiency. Second, in another set of experiments we could see that 
different proteases seem to cause the shedding of TACI from HEK293T in comparison to 
B-cells (data not shown). Although HEK293T cells do not endogenously express TACI 
(208), the usage of human B-cells subtypes that do not express TACI should be discussed 
as a more physiological solution. Therefore, EBV immortalized B-cells from TACI deficient 
CVID patients could be used and checked for different expression and binding abilities for 
BAFF and APRIL after being transduced with either TACI-long or TACI-short. Finally, the 
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ability of our sTACI isoforms to bind to membrane-bound BAFF should be analyzed. 
APRIL cannot be assessed as it is not expressed on the cell surface. The U373 MG cell 
line which is known to express BAFF (and APRIL) could be used and tested for binding of 
both sTACI isoforms (209, 210). It could be evaluated if shedding of BAFF is inhibited by 
sTACI binding which would indicate another negative effect of TACI on immunity. Several 
previous studies examined the possibility of reverse signaling through soluble versions of 
TACI, although no general consensus has been found (59, 211-217). 
 
5.3.2. HOMOTYPIC AND HETEROTYPIC INTERACTION  
 
After assessing oligomerization of our soluble recombinant proteins extensively, 
we wanted to see whether we could extend our findings to membrane-bound TACI. Both 
TACI-long and TACI-short interacted homotypically and heterotypically with each other in 
soluble and membrane-bound form as seen by Co-IP from cells simultaneously 
transfected with TACI-long and TACI-short. This is the first time that a homotypic 
interaction has been described for TACI-short and a heterotypic interaction between both 
receptors. Neither of the TACI isoforms interacted in any way with BCMA.  
Co-Immunoprecipitation is a commonly employed method to analyze protein-
protein interactions (218, 219). This method had already been used before to analyze 
TACI-ligand (136-138, 145) and TACI-TACI interactions (93). One limitation of this 
approach is that we do not know and cannot say whether the proteins form dimers or 
higher oligomers. We can only proof the existence of an interaction. Therefore, FRET 
analysis (220, 221) and Fluorescence Correlation Spectroscopy (FCS) (222-224) could 
be used to give more insight into oligomerization. FRET analysis is based on donor 
acceptor energy transfer (220) and FCS on changes in fluorescence intensity (225). Last, 
the TACI-long/TACI-short heteromers could be analyzed for their functionality within the 
BAFF/APRIL system and existence in vivo, similar to the BAFF and APRIL heteromers 
(88-90).  
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6. CONCLUSION AND OUTLOOK 
 
We observed differences in the binding affinity, decoy function and oligomerization 
between sTACI-long and sTACI-short. This increases our knowledge about the complexity 
of the BAFF/APRIL system. Next, antibodies should be developed that distinguish both 
isoforms and to quantify the relative abundance of both isoforms in human body fluids. In 
previous studies from our lab sTACI was found to be a potentially useful biomarker in MS 
and SLE (93) and also in primary CNS lymphoma (96). The development of ELISAs 
distinguishing the two isoforms of TACI might improve its use as a biomarker.  
Concerning membrane-bound TACI isoforms, further studies with the isoform 
specific antibodies could determine the distribution of both isoforms on different B-cell 
subsets and show which isoform is predominating at which step of B-cell differentiation. 
Next, an association of B-cell pathologies to isoform specific B-cell subsets could be 
analyzed. If an association is found, the isoform specific antibodies could be used 
therapeutically to target directly identified subsets. Moreover, a general effect of B-cell 
depletion therapy such as rituximab on the B-cell repertoire, especially TACI expression, 
could be analyzed to assess whether B-cell depletion changes the population.  
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